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ABSTRACT OF THE DISSERTATION 
 
How CD4+ T Cells Recognize Allostimulatory Peptide-MHC 
 
by 
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Washington University in St. Louis, 2014 
 
Professor Paul M. Allen, Chair 
 
 
Critical in determining transplantation outcome, whether tolerance is achieved or not, are CD4+ 
T cells that can recognize peptides presented on allogeneic (non-self) Major Histocompatibility 
Complex (MHC) molecules in addition to their conventional ligands, peptides presented on self 
MHC. It is an enigma as to how these alloreactive T cells can bind to allogeneic MHC given that 
T cells undergo stringent positive selection during development to bind to peptides presented on 
self MHC. We hypothesize that T cells bind to peptides on non-self MHC using the same 
properties involved in binding their conventional ligands. We identified allostimulatory peptide-
MHC (pMHC) ligands (I-Ek as the allogeneic MHC) for two LLO/I-Ab-specific CD4+ T cells, 
LLO118 and 1G5.1. Both T cells recognized their allostimulatory ligand with a high degree of 
specificity and sensitivity for the allopeptide, similar to how they recognized their cognate 
ligand. Allopeptide recognition was also shown to not merely reflect mimicry of the cognate 
peptide. The integral role of the peptide in alloreactivity was further confirmed by the ability to 
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convert previously non-alloreactive T cell hybrids into becoming responsive with the addition of 
peptide pools. In addition, the binding affinity and kinetics of LLO118 to its allostimulatory and 
cognate pMHC ligands were compared using surface plasmon resonance (Biacore system). 
LLO118 bound its alloligand using similar affinity and kinetics compared to its cognate ligand. 
In comparing alloreactivity with conventional recognition, which has not been done before for 
CD4+ T cells, we have found that similar peptide specificity and binding affinity are used to 
recognize both ligands, shedding light on the fundamental binding properties of the T cell 
receptor (TCR) for pMHC.  
 
Within the population of alloreactive T cells, a significant percentage is comprised of dual TCR 
T cells. This occurs from incomplete allelic exclusion of the TCRα loci during thymic 
development, allowing for simultaneous rearrangement of TCRα on both alleles until positively 
selecting signals are received through the TCR. In dual TCR T cells, only one TCR needs to 
mediate positive selection, and an autoreactive TCR can be masked from negative selection 
through decreased surface expression. This generates a repertoire of T cells containing secondary 
TCRs unconstrained by thymic selection. We set out to investigate the impact of secondary 
TCRα rearrangement to determine what benefit this has on thymic development and further 
define its contribution to peripheral T cell responses. Our hypothesis is that secondary TCRα 
rearrangement positively impacts the development of T cells, but atypical TCR properties that 
arise contribute to alloreactivity and autoimmunity. We examined mice heterozygous for the T 
cell receptor α chain constant region (TCRα+/-), which have only one functional TCRα 
rearrangement. The mice had a defect in generating mature T cells attributable to decreased 
positive selection. Elimination of secondary TCRs did not broadly alter the peripheral T cell 
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compartment, though deep sequencing of the TCRα repertoire demonstrated unique TCRs 
resulting from secondary rearrangements. The functional consequence of these unique TCRs was 
evidenced by the significantly reduced frequencies of TCRα+/- T cell binding to autoantigen and 
alloantigen pMHC tetramers as well as decreased in vivo alloreactivity. Analysis of responses to 
altered peptide ligands (APLs) revealed that dual TCR T cells had increased flexibility in their 
recognition of allogeneic ligands, indicating a mechanism for their importance in alloreactivity. 
Our results show that the role of secondary TCRs in alloreactivity appears to be more significant 
than what has been assumed.  
 
Another factor we wanted to investigate in alloreactivity - as well as in autoimmunity and 
conventional T cell responses - is the effect of MHC composition, specifically the impact of 
increasing the types of MHC molecules expressed. It is perplexing why vertebrates express a 
limited number of MHC molecules when theoretically, having a greater repertoire of MHC 
molecules would increase the number of epitopes presented, thereby enhancing thymic selection 
and T cell response to pathogens. It is possible that any positive effects would either be 
neutralized or outweighed by negative selection restricting the T cell repertoire. We hypothesize 
that the limit on MHC number is due to negative consequences arising from expressing 
additional MHC. We compared T cell responses between B6 mice (I-A+) and B6.E+ mice (I-A+, 
I-E+), the latter expressing a second class II MHC molecule, I-Eb. The naive TCR Vβ repertoire 
was altered in B6.E+ thymi and spleens, suggesting a potential for mediating different outcomes 
in T cell reactivity. In alloreactivity, the B6.E+ T cell response was significantly dampened. We 
wondered if similar effects would be seen in other types of immune responses. The B6 and B6.E+ 
responses to hen egg-white lysozyme (HEL) protein immunization remained similar, but the 
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quality of the T cell response was subtly altered in viral infection and there was markedly 
enhanced susceptibility to experimental autoimmune encephalomyelitis (EAE) in B6.E+ mice. 
The EAE phenotype could be explained by decreased percentage of natural regulatory T cells 
(nTregs) in the B6.E+ mice. Our data suggest that expressing an additional class II MHC can 
produce both positive and negative effects on a wide range of T cell responses. In conclusion, 
new insight into CD4+ T cell alloreactivity has been gained, with our research indicating that 
specificity of peptide binding, weak affinity, flexibility in recognition by dual TCR T cells, and 
MHC composition all contribute significantly to allorecognition. 
	   1	  
 
 
 
 
 
CHAPTER I 
 
 
Introduction 
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The ability of T cell receptors (TCRs) to recognize peptides presented on allogeneic (non-self) 
Major Histocompatibility Complex (MHC) molecules presents a fascinating puzzle to 
immunologists. TCRs are generated randomly through gene rearrangement and are then 
subjected to strict selection processes during T cell development to bind self MHC, but not so 
strongly that they would cause autoimmunity in the periphery. Knowing this, why can a 
significant portion of TCRs recognize allogeneic MHC, and what are the factors driving the 
participation of T cells in altered reactivities? In this chapter, I will review TCR generation and 
selection, discuss what we know about the characteristics of T cell binding to allogeneic pMHC, 
and introduce factors in selection – namely secondary TCRα rearrangement and MHC 
composition – that may unduly influence T cell alloreactivity as well as autoimmunity, another 
type of immune response that eludes thymic selection processes. Here, alloreactivity is not 
merely an interesting enigma to ponder, but an area of study that could shed light on fundamental 
T cell binding properties and factors leading to unwanted immune responses. 
 
I. T cell development and ligand recognition 
 
I.I. Positive and negative selection in the thymus lead to the development of self MHC-
restricted yet non-autoreactive T cells 
 
T cells are a critical component of the adaptive immune system, with antigen recognition by 
TCRs initiating a cascade of events including cytokine production, activation of other cells, and 
elimination of cells infected with pathogens, amongst other things. The TCR is comprised of 
TCRα and TCRβ chains generated by gene segment recombination during thymocyte 
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development. The process of gene rearrangement is important for generating a functional T cell 
repertoire. First, the TCRβ chain rearranges in CD4 and CD8 double-negative (DN) thymocytes 
under stringent allelic exclusion and ceases when an in-frame product is made and expressed (1, 
2). CD4 and CD8 co-receptors become upregulated, and in these double-positive (DP) cells 
TCRα chain recombination occurs until halted by positively selecting signals through the TCR 
(3, 4). Unlike the TCRβ locus, there is a lack of allelic exclusion for TCRα, evidenced by 
thymocytes and peripheral T cells with 2 in-frame rearrangements of TCRα (2, 5) as well as 
mature T cells with dual TCR expression on the surface (6-8). As it is a difficult process for 
thymocytes to successfully undergo positive selection, with approximately 90% of thymocytes 
dying (9-13), having simultaneous and iterative TCRα rearrangement on both chromosomes 
would presumably increase the chances of generating a TCR that can bind peptide-MHC 
(pMHC) (14). At the end of thymic development, a positively selected T cell downregulates one 
co-receptor and matures into a CD4 or CD8 single-positive (SP) cell, depending on whether its 
TCR is specific to MHC class II or class I molecules, respectively (10). 
 
Two selection processes in thymic development act to generate T cells that can recognize self 
MHC yet remain tolerant to self. Positive selection leads to the survival of T cells that can 
recognize self-pMHC ligands on cortical thymic epithelial cells, allowing peripheral T cells to 
become activated by self MHC molecules presenting cognate ligands (10, 15-17). Negative 
selection is induced by medullary thymic epithelial cells and bone marrow derived antigen 
presenting cells (APCs) to delete T cells containing TCRs with high affinity to self-pMHC, 
preserving self-tolerance (11, 18). Approximately 5% of thymocytes are eliminated through 
negative selection mediated by a single MHC molecule (19).  
	   4	  
 
I.II. T cells that recognize allogeneic MHC or autoligands can result despite stringent 
thymic selection processes  
 
Although during thymic development T cells are selected to be responsive to peptides on self 
MHC, an astounding percentage of T cells in the periphery are capable of reacting to peptides on 
allogeneic, or non-self, MHC. In fact, it is estimated that 1-10% of T cells are alloreactive, 
approximately 1,000-fold higher than the percentage of T cells that can bind their cognate 
ligands on self MHC (20-22). An explanation for this phenomenon, discussed in greater detail in 
a subsequent section, is that there is germline affinity of the TCR for MHC molecules, leading to 
an ability of T cells to bind MHC molecules they have not encountered in the thymus. 
 
Additionally, negative selection is not a perfect process, with low avidity, self-reactive T cells 
escaping negative selection and migrating to the periphery. And, not all peripheral antigens are 
expressed or presented sufficiently in the thymus to allow for elimination of autoreactive T cells. 
Though peripheral tolerance mechanisms are in place, autoimmunity may still ensue when it is 
broken by the release of self antigens through tissue damage or by infection with a pathogen 
containing epitopes similar to self peptides (23).  
 
I.III. T cells exhibit distinct binding properties to peptide-MHC ligands 
 
The TCR recognizes antigen comprised of peptide bound to MHC molecules expressed on the 
surface of other cells. How the TCR interacts with pMHC is one of the most distinctive features 
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of T cell biology. MHC class I-restricted TCRs bind to peptides of approximately 8-10 residues 
that can bulge outwards from the MHC peptide-binding groove. The ligand for MHC class II-
restricted TCRs consists of longer peptides that can extend past the open grooves of the MHC 
(24). TCRs interact with pMHC using characteristically weak affinity (approximately 1 - 
100µM), slow on-rates, and fast off-rates (25, 26). Interestingly, despite this weak affinity 
interaction, ligand recognition by TCRs occurs with exquisite specificity as well as plasticity. 
The specificity of recognition is seen with varying T cell responses to subtly different APLs and 
drastically divergent T cell fates – death by neglect, positive selection, and negative selection – 
upon encountering pMHC ligands in the thymus. TCR plasticity is the fundamental ability of 
TCRs selected on endogenous peptides presented by self MHC to react to pathogen-derived 
peptides in the periphery (27, 28). Another characteristic feature of TCRs is that they generally 
sit over the peptide-MHC in a similar, diagonal orientation relative to the long axis of the 
peptide-binding groove, with the TCR Vα domain contacting the N-terminus of the peptide and 
the TCR Vβ domain at the C-terminus end. Contacts with the MHC are primarily made by the 
germline-encoded CDR1 and CDR2 loops of the TCR, whereas the somatically rearranged 
CDR3 loops bind to the highly variable peptide portion (24). 
 
 
II. CD4+ T cells in alloreactivity 
 
II.I. Germline-encoded affinity of TCR for MHC provides an explanation for alloreactivity 
 
It has also been proposed that the phenomenon of alloreactivity is a manifestation of the 
propensity of TCRs to bind MHC. Whether this propensity results from an intrinsic affinity of 
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TCR for MHC or from thymic selection restricting the T cell repertoire to TCRs that can bind to 
MHC has been a fiercely debated topic. In support of the latter possibility, it was found in a 
structural analysis of 8 TCRs co-complexed with MHC class I that the structures could be split 
into 2 groups – 4 TCRs in each group – based on the location on the peptide-MHC surface where 
the TCR Vα domains contacted. Interestingly, 1 group consisted of CD8-dependent TCRs, while 
the other group had the CD8-independent TCRs (29). This observation lends support to the idea 
that extrinsic factors, such as the co-receptor, contribute to how TCRs bind to their ligands. 
Additionally, the Lck sequestration model of thymic selection proposes that the association of 
the signaling protein tyrosine kinase, Lck, with the CD4 and CD8 co-receptors only allows 
thymocytes with MHC-restricted TCRs able to bind pMHC along with their co-receptor to 
transduce positive selection signals and mature. That the expression of co-receptor-free Lck 
instead of co-receptor-associated Lck was sufficient to select out an MHC-independent T cell 
repertoire supports the idea of Lck association with co-receptors mediating the generation of 
MHC-restricted T cells (30). 
 
On the other hand, an elegant set of experiments has been performed to demonstrate that the 
TCR repertoire prior to MHC selection has an inherent affinity for MHC molecules. In this 
study, thymi from MHC-deficient mice were matured in organ cultures by treatment with 
antibodies to TCR and CD4. Upon stimulation with allogeneic cells, the frequency of 
responding, pre-selection CD4+ T cells was comparable to the alloreactive frequency of MHC-
selected CD4+ T cells derived from thymic organ cultures from MHC class II sufficient mice 
(31). Another study probed the effects of thymic negative selection on TCR-MHC interactions. 
CD4+ T cells from wild-type mice were compared to cells derived from mice expressing I-Ab 
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with a single peptide, in which positive selection can still occur but negative selection is severely 
limited. This study noted that with decreased negative selection, T cells overall were much more 
reactive to allogeneic MHC (32). Thus, it appears there is an intrinsic ability of TCRs to broadly 
recognize MHC, but this becomes constrained by negative selection.  
 
Building upon this idea of inherent TCR affinity for MHC, recent studies have reported 
convincing data documenting germline-encoded interactions between TCR and MHC. A 
structural analysis of 4 Vβ 8.2 TCRs complexed with their pMHC ligands revealed that they bind 
nearly identically despite differences in the TCRβ D and J segments, TCR Vα chains, and the 
pMHC recognized. In particular, 3 amino acids in the Vβ CDR2 loop – Tyr48, Tyr50, and Glu56 
– made remarkably conserved interactions with residues on the MHC (33). These TCR Vβ amino 
acids were demonstrated to be required for efficient thymic selection, as mice with a modified 
TCR Vβ repertoire, expressing only a TCR Vβ8 chain containing an alanine substitution at any 
of the 3 residues (paired with the full TCRα repertoire), yielded decreased numbers of mature T 
cells. That the same result was seen when one of these amino acids was mutated in a different β 
chain family – TCRβ6 – is convincing evidence for conserved interactions between TCRs and 
MHC, lending credence to the idea of an inherent TCR affinity for MHC (34). 
 
II.II. There is increasing evidence that the peptide is highly involved in alloreactivity  
 
Whether or not interactions between TCRs and the peptides bound to MHC also contribute to 
allorecognition is an important question for understanding the molecular basis behind T cell 
alloreactivity. A convincing study demonstrating the importance of the peptide utilized H2-DMα-
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/- mice as donor organs in a transplantation experiment. Without H2-DMα, MHC class II 
molecules are primarily associated with an invariant chain peptide (clip), significantly decreasing 
the repertoire of peptides presented to CD4+ T cells. Interestingly, H2-DMα-/- (H-2b) cardiac 
grafts survived much longer than B6 wild-type grafts in H-2d recipient mice, accompanied by a 
diminished host T cell response, demonstrating the considerable impact of the peptide in 
mounting an alloreactive response (35). The importance of allopeptides for MHC class I-
restricted T cells has also been documented. Analysis of the 2C TCR binding to an alloligand, 
dEV8 peptide presented by H-2Kbm3, revealed that an MHC residue responsible for 
allorecognition repositions the presented peptide, and this peptide alteration dramatically 
changes how the TCR recognizes the pMHC surface to allow for allo-pMHC binding (36). 
 
Additionally, the specificity of the T cell alloresponse to peptides has been shown. Cytotoxic T 
lymphocyte (CTL) clones generated to be alloreactive to murine cytomegalovirus (MCMV) 
antigen presented by H-2Ld showed exquisite peptide specificity, as they were unable to 
recognize other viral or endogenous Ld peptides (37). Three T cells alloreactive to I-Ek were each 
identified by our lab to respond to multiple I-Ek peptides. We demonstrated that allopeptide 
mutants attenuated T cell responses, so peptide specificity rather than degeneracy explained the 
ability of the T cells to react to multiple allostimulatory pMHC ligands. The TCRs also bound 
differently to each allopeptide-I-Ek surface, suggesting that the presented peptide makes 
important contributions to how alloreactive TCRs approach and bind their ligands (38). 
Furthermore, another study from our lab showed that the self-peptide repertoire limits the ability 
of T cells to be alloreactive. A panel of T cell hybrids not alloreactive to H-2k or H-2p could be 
converted to becoming alloreactive upon addition of peptide mimotope pools with H-2k or H-2p 
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MHC binding anchors and all 20 amino acid options at TCR contact positions, demonstrating 
that the endogenous peptide repertoire is a limiter on alloreactivity (39). This result allows us to 
reconcile the idea that TCRs have inherent affinity for MHC and the observation that not all T 
cells are alloreactive.  
 
II.III. It is unknown how CD4+ T cell alloreactivity compares to conventional recognition 
 
All of the observations about T cell alloreactivity suggest that alloreactive T cells would require 
important contacts with both the allopeptide and MHC to bind, but whether this binding looks 
similar or different compared to recognition of cognate pMHC is still an unresolved issue. An 
understanding of this would yield insight into the fundamental properties of TCR-pMHC 
binding. Assessing crystal structures of TCRs co-complexed with both allostimulatory and 
cognate pMHC ligands is the best way to compare the detailed chemical interactions between 
alloreactive and conventional T cell recognition. To date, there are only 2 known studies 
comparing TCRs co-complexed with distinct allostimulatory and cognate ligands, and both 
involve MHC class I-restricted TCRs. One study compared structures of the 2C TCR in complex 
with its allostimulatory ligand, the QL9 peptide presented on H-2Ld, and in complex with its 
cognate ligand, dEV8 peptide on H-2Kb. Results from this investigation showed that the 2C TCR 
binds to its two ligands fairly dissimilarly. For instance, 2C binds more perpendicularly to QL9-
Ld relative to the long axis of the MHC groove compared to dEV8-Kb. As a result, there are 
many pairwise interactions that are unique between the two co-complexes. 4 TCR-MHC contacts 
are identical between the two, but given the 80% sequence identity of the Kb and Ld helices, a 
few preserved contacts would be predicted (40).  
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A study of the LC13 TCR, however, suggested a different mechanism for how a TCR binds to its 
allostimulatory pMHC ligand. Here, crystal structures were compared between LC13 in complex 
with an allopeptide on HLA-B*4405 and in complex with its cognate ligand, a viral peptide 
presented on HLA-B*0801. Though the surface-exposed residues of the 2 MHC molecules are 
not highly similar – 5 amino acids are different between the 2 – the footprints of LC13 on the 
MHC surfaces revealed striking similarity in binding. Additionally, 3 C-terminal residues of the 
viral peptide known to be critical for contact (P6-Ala, P7-Tyr, P8-Gly) are not identical to the 
corresponding residues of the allopeptide (P6-Ala, P7-Phe, P8-Thr), yet the LC13 TCR binds to 
both peptide ends with highly similar interactions, making conserved hydrogen bonds to the 
peptide backbone despite the different amino acid side chains. Thus, the authors concluded that 
molecular mimicry is the mechanism for how alloreactive TCRs bind to their ligands (41). 
Whether CD4+ T cell alloreactivity is different from or similar to conventional recognition, 
whether it follows the conclusions drawn from 2C or LC13, remains to be determined. Work 
comparing CD4+ T cell recognition of an autoantigen and foreign antigen showed that reactivity 
to the two ligands involves conserved peptide recognition and only a small number of amino acid 
differences on the MHC surface (42). It is unknown whether this observation of CD4+ T cell 
mimicry would also be seen when comparing CD4+ T cell alloantigen and foreign antigen 
recognition. 
 
 
II.IV. Dual TCR T cells contribute disproportionately to alloreactivity 
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The lack of allelic exclusion for TCRα results in 1-10% of peripheral T cells in mice and humans 
expressing 2 functional TCRs on the cell surface (7). In these cells, each TCRα chain pairs with 
the same β chain, giving the cell 2 distinct pMHC ligand specificities (43-45). Not all the T cells 
with two rearranged alpha chains express two TCRs on the cell surface, due primarily to 
preferential pairing of α and β and the degradation of unpaired α chains (2, 8, 46). There has 
been some debate on whether the secondary TCR, which most likely is not involved in positive 
selection, actually exerts an important role in peripheral immune responses. In particular, it is 
intriguing to wonder whether dual TCR T cells play a role in atypical immune reactions such as 
alloreactivity and autoimmunity. T cells with 2 TCRs may not follow stringent selection 
requirements during thymic development. One TCR can successfully mediate positive selection, 
freeing the secondary TCR from participating in positive selection and needing to bind self 
pMHC (43, 44). Additionally, the expression of secondary TCRs can mask autoreactive TCRs 
from deletion, likely due to TCRα chain competition for the single TCRβ chain decreasing the 
surface expression of the pathogenic TCR (47).  
 
There are reports that the secondary TCR is not required for autoimmune diseases such as 
arthritis, experimental autoimmune encephalomyelitis (EAE), and lupus (48, 49). On the other 
hand, the contribution of naturally-arising dual TCR T cells to autoimmunity has been shown for 
diabetes using NOD mice (49). The impact of dual TCR T cells on alloreactivity has also been 
investigated. Using TCRα+/- mice which are heterozygous for a mutation in the T cell receptor α 
chain constant region that disrupts the formation of a functional TCRα chain, resulting in the 
lack of dual TCR T cells, our lab demonstrated that secondary TCRs were responsible for over 
40% of the alloreactive response even though they constitute only about 10% of the peripheral T 
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cell repertoire (44). Additionally, we demonstrated the impact of secondary TCRs on 
alloreactivity in patients with acute graft versus host disease (GVHD) after allogeneic 
hematopoietic stem cell transplantation. In these patients, dual TCR T cells were expanded, 
activated, and responded preferentially to mismatched alloantigens (50). In addition to having an 
impact in autoimmunity and alloreactivity, secondary TCRs were also shown to contribute to the 
response to a foreign ligand (43).  
 
III. The effect on T cell responses from expressing additional MHC molecules in mice 
 
III.I. MHC composition affects alloreactivity 
 
There is evidence that the composition of the positively and negatively selecting MHC molecules 
can shape the alloreactive T cell repertoire. In studying the repertoire of T cells resulting from 
selection with a single peptide-MHC class II molecule – a system that can positively select a full 
repertoire of T cells but exhibits limited negative selection – it was revealed that positive 
selection results in T cells that can bind to many different allogeneic MHC molecules, with 
negative selection establishing MHC restriction (32). Germ-line affinity of T cells for MHC can 
also impact the formation of the alloreactive T cell repertoire; CD4+ TCRs that contain mutations 
of Vβ amino acids identified to mediate MHC binding could no longer respond to the majority of 
allogeneic MHC haplotypes tested (34). In studying the relationship between the selecting MHC 
and allostimulatory MHC, it was discovered that the avidity of the 2C T cell for its alloantigen is 
affected by what MHC is present during selection (51). Along the same line, allopeptide 
recognition can be influenced by the homology of the stimulatory MHC to the self MHC 
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molecule (52). Altogether, it would appear that the MHC present during selection affects the 
alloreactive T cell population.  
 
III.II. Adding MHC molecules to the repertoire has conflicting results on T cell immunity 
 
It is an interesting question as to why more types of MHC molecules are not expressed by 
vertebrates. As the MHC plays an integral role in selecting mature T cells and presenting 
pathogenic peptides in the periphery (53), having more MHC would theoretically be beneficial, 
resulting in more T cells that make it past positive selection and an increased ability to respond 
to pathogens. Indeed, mathematical modeling suggests that the number of MHC molecules can 
be increased significantly, up to as many as 1,500 MHC molecules, without suffering adverse 
effects on the ability to mount a response to pathogens (54, 55). The question of what impact 
expressing additional MHC molecules has on the immune response has intrigued immunologists 
over the years yet has not been answered thoroughly. 
 
Currently in the field, there are conflicting reports on whether increasing the repertoire of MHC 
molecules expressed would be beneficial or detrimental to immune responses. MHC 
heterozygotes – obtained from crossing the F1 progeny of MHC-congenic mice – were shown to 
have greater pathogen resistance compared to their littermate MHC homozygote mice (56, 57). 
On the other hand, studies looking at the F1 progeny of parents with disparate MHC haplotypes 
revealed a dampening of T cell reactivity in the context of viral infections. Both naive T cell 
precursor numbers and T cell cytokine production during infection with influenza and vaccinia 
viruses were shown to be reduced (58, 59). The approach of looking at MHC heterozygote mice, 
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however, is a complicated system that may result in heterogeneous responses in offspring within 
the same cross due to complex contributions from the varied MHC molecules (60).  
 
An alternative, simpler method is to investigate the effects of adding just one more MHC 
molecule. Studies employing this method focused on autoimmunity, with most concluding that 
expressing more MHC is beneficial. Adding I-E expression to the non-obese diabetic (NOD) 
background protected from diabetes, with I-E-mediated thymic deletion of pathogenic Vβ5 TCR-
expressing T cells proposed to be a mechanism (61-64). Expression of I-E on other backgrounds 
including H-2b and H-2q likewise resulted in protection from lupus, experimental autoimmune 
myasthenia gravis, and collagen-induced arthritis (65-67). Yet there is a report that the addition 
of I-Eb actually resulted in detrimental effects, enhancing susceptibility to disease in autoimmune 
thyroiditis (68). Having negative effects from the addition of MHC was also corroborated in a 
different model (viral infection) with a different MHC being investigated (I-A) (69). What effect 
expressing additional MHC molecules exerts on alloreactivity has not been tested. And, the 
previous studies summarized here have each focused only on one disease model. It remains 
unknown whether adding a particular MHC exerts distinct effects on different T cell responses. 
 
Conclusion 
The studies on T cell alloreactivity have revealed incredible insight into the factors contributing 
to alloreactivity. Germline-affinity of TCRs for MHC molecules and recognition of the presented 
allopeptide have been shown to be important in allorecognition. Compared to conventional 
recognition, CD8+ T cell alloreactivity can mimic conventional recognition as well as involve 
disparate binding mechanisms, though how CD4+ T cell alloreactivity compares is unknown. 
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Additionally, it was discovered that secondary TCRα rearrangement, which generates dual TCR 
T cells, contributes disproportionately to alloreactivity as well as to some types of autoimmunity. 
What benefit this process has in thymic development remains to be seen. And, MHC 
composition, specifically how many types of MHC molecules are expressed, has been shown to 
affect autoimmunity with its role in alloreactivity suggested but not yet determined.
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CHAPTER II 
 
 
 
Identification of alloligands for CD4+ T cells and comparison of allorecognition with 
conventional recognition reveal similarities 
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Introduction 
 
An enigma in T cell biology is how T cells are able to recognize allogeneic MHC after 
undergoing stringent selection processes during thymic development to bind self MHC. It is 
particularly puzzling that such a high frequency of T cells are alloreactive, between 1-10% (1, 2). 
Germline affinity of TCRs for MHC, in which conserved amino acids in the TCR CDR1 and 
CDR2 loops consistently bind to similar regions on the MHC, has been proposed to explain this 
phenomenon (3). As recognition of allogeneic MHC has not been limited by negative selection, 
it is conceivable that a high percentage of T cells recognize allogeneic MHC, an idea supported 
by the finding that limited negative selection yields a T cell repertoire that is more alloreactive 
(4). Convincing experimental evidence in support of germline affinity as a basis for alloreactivity 
includes decreased alloreactivity after mutating the conserved TCR CDR1 and CDR2 amino 
acids as well as dependence on these residues for allorecognition after altering the peptide-
contacting CDR3 loop (5, 6).  
 
A longstanding question of T cell alloreactivity is how it compares to conventional recognition 
of foreign peptides presented by self MHC. Studies thus far have started to show that 
alloreactivity utilizes fundamental properties seen in conventional T cell recognition of pMHC. 
A study of CTL clones generated to be alloreactive to MCMV peptide presented by H-2Ld 
revealed that alloreactivity exhibits peptide- and MHC-specificity (7). Additionally, comparable 
MHC binding was found for CTLs recognizing H-2Ld as an alloligand compared to CTLs 
binding it as its syngneic MHC (8). Polyspecificity in alloreactivity has been documented, with 
alloreactive CD4+ T cell hybrids recognizing each of their distinct allopeptide ligands with a high 
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degree of peptide specificity and utilizing different MHC contacts when bound to each peptide 
(9). Regarding binding affinity and mechanisms for T cell alloreactivity, differences between 
alloreactivity and conventional recognition were noted. Using the 2C TCR system, it was found 
that binding to the allogeneic MHC H-2Ld is an order of magnitude stronger than binding to the 
syngeneic MHC H-2Kb (10) with additional differences in enthalpy- and entropy-driven binding 
(11). The most direct way to understand how alloreactivity relates to conventional recognition is 
to compare how one T cell binds to its alloligand versus its cognate ligand. To date, T cells with 
identified paired ligands (distinct from each other) that have been used for this analysis have 
been restricted to CD8+ T cells. These studies found that CD8+ T cell alloreactivity can reflect 
molecular mimicry (12) as well as bind with divergent mechanisms compared to conventional 
recognition (11).  
 
Ligand recognition by CD4+ T cells is of a dissimilar nature compared to CD8+ T cells; not only 
does the pMHC surface look different, but the CD4 co-receptor itself also binds less strongly to 
MHC and is associated with more Lck, affecting signaling downstream of TCR activation (13-
15). Thus, the conclusions drawn from CD8+ T cell alloreactivity cannot be applied to 
understanding whether CD4+ T cell alloreactivity is similar or different compared to 
conventional recognition. We hypothesize that CD4+ T cell alloreactivity is similar to 
conventional recognition and exhibits the same binding properties. To address this, we identified 
paired ligands (allo and cognate pMHC ligands) for multiple CD4+ T cells and compared how 
they recognize their alloligands and cognate ligands, assessing the specificity of peptide 
recognition and binding kinetics. For one T cell responsive to Listeriolysin O (LLO)/I-Ab as its 
cognate ligand, LLO118, we found that it is naturally alloreactive to I-Ek. Subsequent screening 
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of a 95 I-Ek peptide library identified one allopeptide for LLO118. Another T cell also 
responsive to LLO/I-Ab as its cognate ligand, 1G5.1, was not naturally alloreactive to H-2k. 
However, we were able to identify an I-Ek allopeptide mimic for the T cell using peptide pools 
with a hemoglobin (Hb) epitope as the peptide backbone and multiple amino acid options at the 
TCR contact sites. Studies in the field have successfully used allopeptide mimics to examine 
alloreactivity (16), even resulting in conclusions identical to those obtained from studying a 
related, naturally occurring allopeptide (12). Additionally, we found that T cell alloreactivity is 
limited by the endogenous peptide repertoire, necessitating the use of peptide mimics to study 
the alloreactive potential of T cells. Comparison of LLO118 and 1G5.1 peptide binding for 
cognate recognition versus alloreactivity revealed that mimicry did not explain the ability of the 
T cells to be alloreactive as well as demonstrated a high degree of specificity in binding. 
Additionally, binding affinity and kinetics studies using surface plasmon resonance revealed that 
LLO118 binds with similar affinity and kinetics to both its cognate and allostimulatory ligands. 
Our data therefore suggest that CD4+ T cell alloreactivity is of a similar nature compared to 
conventional recognition, providing insight into universal properties of T cell binding. 
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Results 
 
The LLO/I-Ab-specific T cell, LLO118, is naturally alloreactive to kidins220/I-Ek 
 
LLO118 is a CD4+ Vα2, Vβ2 T cell hybrid that was originally generated in the Unanue lab 
(unpublished data). With antibodies available to both TCRα and TCRβ chains as well as LLO118 
TCR transgenic mice on the RAG-/- background made, this T cell has many useful reagents for 
probing immunologic questions. Specific to LLO190-201 presented by I-Ab as measured by 
enzyme-linked immunosorbent assay (ELISA) for IL-2 production (Fig. 2.1A), LLO118 was 
also determined to be alloreactive, with significantly increased IL-2 production to irradiated 
B6.K (H-2k) APCs compared to medium. The alloresponse was directed to I-Ek, as blocking 
antibodies to I-Ek abrogated the IL-2 response to H-2k APCs (Fig. 2.1B). We sought to identify 
its I-Ek-restricted allopeptide in order to have two defined ligands and directly compare 
alloreactive and conventional recognition. To do this, we utilized a library of 95 self-peptides 
eluted from I-Ek, previously used by our lab to successfully identify allopeptides for 9 out of 32 
alloreactive T cells (9). We used this library to screen for an allopeptide able to stimulate 
LLO118 IL-2 production upon addition of peptide to Chinese hamster ovary (CHO) cells stably 
transfected with I-Ek (CHO-Ek), which have limited endogenous peptides and do not stimulate 
LLO118 on their own. One peptide (#75) from the library was able to stimulate IL-2 production 
from LLO118 in a dose-dependent manner. The lack of stimulation from peptide #10 is 
representative of the results obtained from the rest of the peptides in the library (Fig. 2.1C). 
Peptide #75 is derived from a predicted kinase D-interacting substrate of 220 kDal (kidins220). 
Thus, we now have two defined ligands for LLO118: its cognate ligand LLO/I-Ab and its 
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alloligand kidins220/I-Ek. 
 
An I-Ek allopeptide mimic can be identified for the LLO/I-Ab-specific T cell, 1G5.1 
 
1G5.1, a Vα1, Vβ1 CD4+ T cell hybridoma, was generated by immunizing B6 TCR Cα+/- mice 
containing a fixed 2.102β chain with the LLO190-201 peptide (that is presented by I-Ab). 
Heterozygosity at TCR Cα prevents the expression of dual TCRs in the hybrids, and the β chain 
is from the well-defined 2.102 T cell specific for Hb/I-Ek (17). Reactivity to LLO is shown by 
IL-2 production measured by ELISA (Fig. 2.2A). Although 1G5.1 was not naturally alloreactive 
to H-2k APCs (Fig. 2.2B), we sought to identify an I-Ek allopeptide mimic for it because a 
second T cell with defined, paired pMHC ligands in addition to LLO118 would enhance our 
investigations into how alloreactivity compares to conventional recognition as well as broaden 
the applicability of the conclusions drawn from our comparisons. To identify an allostimulatory 
mimotope for 1G5.1, we screened pools of peptides consisting of the I-Ek-binding Hb epitope as 
the backbone, reasoning that the 2.102 TCRβ chain may predispose the TCR to recognize Hb 
and facilitate our screen. The pools contained different amino acid groups substituted at TCR 
contact P3 in addition to all 20 amino acid possibilities (denoted as “X”) at P5. Conversely, we 
also screened peptide pools consisting of all 20 amino acids at P3 with more limited amino acid 
groups at P5. Three peptide pools each containing groups of 4 amino acids at P3 and all 20 
options at P5 elicited T cell responses. One pool with all 20 amino acids at P3 and D,E,N,Q at P5 
also provoked T cell production of IL-2 (Fig. 2.3A). These pools were deconvoluted into the Hb 
peptide with single amino acid substitutions based on the amino acids present in the stimulatory 
pools. A phenylalanine (F) at P3 resulted in the most IL-2 production (Fig. 2.3B). This 
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allopeptide mimic, Hb F70, was purified, analyzed by mass spectrometry, and tested for its 
ability to stimulate 1G5.1. The T cell response to Hb F70 was dose-dependent and highly 
sensitive (Fig. 2.3C). 
 
Allopeptide recognition by CD4+ T cells is specific  
 
Reports of how CD8+ T cell alloreactivity compares to conventional recognition have revealed 
that it involves mimicry of cognate pMHC binding (12) or encompasses divergent binding 
mechanisms (11). Upon initial characterization, the peptide sequences of cognate and 
allostimulatory peptides for 1G5.1 and LLO118 are not similar at the TCR contact sites (Fig. 
2.4A). To test if mimicry can explain LLO118 and 1G5.1 allopeptide binding, APLs were 
generated and tested to see if alloresponses could still occur when amino acids at the TCR 
contact positions P2, P3, or P5 of the allopeptides are replaced with the corresponding amino 
acids from the cognate peptides. As measured by IL-2 ELISA, LLO118 and 1G5.1 did not 
respond or responded minimally to these APLs (Fig. 2.4B). Likewise, APLs of the cognate 
peptide, LLO, containing amino acids from the allopeptides at the TCR contact positions did not 
stimulate significant responses from LLO118 and 1G5.1 (Fig. 2.4C). Therefore, peptide mimicry 
cannot explain LLO118 and 1G5.1 alloreactivity. Thus far, with the APLs tested, it appears that 
alloreactivity is peptide-specific. Knowing that a fundamental property of conventional T cell 
recognition is a high degree of peptide specificity, we sought to rigorously determine whether 
CD4+ T cells exhibit similar allopeptide specificity. Our results will contribute to understanding 
whether CD4+ T cell alloreactivity is inherently different or strikingly similar to conventional 
recognition. A comprehensive series of APLs containing single amino acid substitutions at TCR 
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contact sites P2, P3, or P5 were generated for both the allopeptides and cognate ligands. 
Substitutions with both conserved and disparate residues were made. LLO118 and 1G5.1 
responses to the APLs were severely attenuated in comparison to wild-type peptides, suggesting 
peptide specificity is involved in allorecognition (Fig. 2.5). 
 
That the allopeptide is recognized as a distinct surface from the cognate peptide and with a high 
degree of specificity suggest that recognition of a particular allopeptide is required for CD4+ T 
cell allorecognition. Seeing that not all T cells are naturally alloreactive, we wondered if 
providing T cells with an increased repertoire of allopeptides would be sufficient to enable 
alloreactivity. We took a panel of I-Ab-restricted CD4+ T cell hybrids not naturally alloreactive 
to H-2k or H-2p APCs and investigated whether adding peptide mimotope pools to the APCs 
would result in reactivity. Using IL-2 ELISA as a read-out, we saw that the addition of peptide 
pools comprised of I-Ek or I-Ep MHC anchor residues plus all 20 amino acid options at the TCR 
contact sites P2, P3, P5, and P8 yielded responses from the T cell hybrids (Fig 2.6A). 
Deconvolution of the peptide pools was performed by substituting more limited pools of 4 amino 
acid options at one TCR contact site in conjunction with unlimited amino acids at the other 3 
contact sites, then further deconvoluting into single peptide species depending on the patterns of 
reactivity to yield individual allopeptide mimotopes for each T cell hybrid. We saw that 
recognition of the allopeptide mimotopes was highly specific, as APLs with mutated residues at 
P3 or P5 strongly inhibited alloreactivity (Fig. 2.6B). This is consistent with our LLO118 and 
1G5.1 data and what others noticed in previous studies of allopeptide specificity (7, 9). Put 
together, our results indicate that recognition of the allopeptide is not merely mimicry of the 
cognate peptide, allopeptide response is highly specific, and expanding the peptide repertoire is 
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sufficient for enabling allorecognition of otherwise non-alloreactive T cells. 
 
LLO118 binds its alloligand and cognate ligand with similar binding affinity and kinetics 
 
Weak affinity, slow association, and fast dissociation are all characteristic properties of T cell 
recognition of conventional ligands (18, 19). We used surface plasmon resonance (Biacore 
system) to measure kinetics and determine whether CD4+ T cells use these same properties to 
bind to their allostimulatory ligands or whether the properties of allorecognition are inherently 
different. LLO/I-Ab and kidins220/I-Ek were coupled to a Biacore CM5 chip. Soluble single 
chain (sc) LLO118, with the TCR Vα and Vβ chains expressed as a single-chain construct, was 
injected and flowed over the chip until equilibrium was reached. We saw that the on-rate, off-
rate, and binding affinities were similar between scLLO118 binding to its cognate ligand and its 
alloligand (Fig. 2.7, Table 2.1). Additionally, binding affinities were weak and within the 1-
100µM range typically reported for TCR-pMHC interactions, confirming the values obtained 
were reasonable. 
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Discussion 
 
Much insight has been gained in understanding T cell alloreactivity by our lab and others. This 
includes the remarkable discovery of germline-encoded contacts between TCR and MHC and 
recent findings that suggest an importance for the allopeptide in alloreactivity. However, there 
are still questions about how CD4+ T cells bind to allostimulatory pMHC ligands that remain 
unanswered and are integral for gaining a full picture of how alloreactivity occurs. Namely, how 
does CD4+ T cell alloreactivity compare to recognition of cognate ligands? Finding an answer to 
this question is important because we still do not know whether CD4+ T cell alloreactivity is 
fundamentally similar to conventional recognition or whether it embodies divergent binding 
mechanisms, with either scenario having important implications for understanding fundamental 
T cell binding properties. To address this issue, the identification of paired ligands, 
allostimulatory and cognate, was performed for two CD4+ T cells, LLO118 and 1G5.1. These T 
cells were then used to directly compare alloreactive and conventional recognition, revealing a 
high degree of peptide specificity in both types of recognition. Additionally, we found that 
molecular mimicry of the cognate peptide could not explain the ability of the T cells to respond 
to the allopeptide. Further emphasizing the importance of the peptide in alloreactivity, we 
determined that naturally non-alloreactive CD4+ T cells could be converted to becoming 
alloreactive by the addition of allopeptide mimotopes, suggesting that the endogenous repertoire 
of peptides is a limiting factor for T cell alloreactivity. Finally, biochemical studies of LLO118 
suggested very similar binding kinetics and affinity values between alloreactivity and cognate 
recognition. Thus far, these studies of CD4+ T cells favor the interpretation that alloreactivity 
exhibits highly similar binding properties compared to cognate pMHC recognition. 
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We currently do not know how LLO118 and 1G5.1 bind their allogeneic MHC compared to their 
syngeneic MHC. Crystal structures of these TCRs co-complexed with their allostimulatory and 
cognate pMHC ligands would best elucidate which MHC residues are contacted and how. Our 
prediction is that the TCRs would bind their ligands distinctly. Structural comparison of the 
MHC class I restricted TCR 2C complexed with its allo- and cognate-pMHC ligands revealed 
highly divergent binding footprints of the TCR on the two surfaces, with a more perpendicular 
TCR binding orientation on the alloligand relative to the long axis of the MHC groove (11). 
Though no comparable crystal structure comparison for MHC class II restricted TCRs has been 
done, analysis of CD4+ T cell recognition of multiple allo-pMHC ligands (dissimilar peptides 
presented by I-Ek) has been performed. Using a panel of MHC mutants each with a different 
surface residue disrupted, it was found that these CD4+ T cells recognize their I-Ek alloligands 
distinctly (9). The allopeptides and cognate peptides for LLO118 and 1G5.1 are likewise 
different, and distinct MHC binding would be predicted. Although greatly similar TCR contacts 
with MHC were seen in LC13 binding to its cognate ligand and alloligands, in this case the 
peptide binding mechanisms were identical, with the TCR CDR3 loops contacting conserved C-
terminus features in both the cognate and allostimulatory peptides (12). No such peptide mimicry 
was seen in LLO118 and 1G5.1, so we would not anticipate similar MHC contacts between the 
allo- and cognate-MHC molecules.  
 
A fundamental understanding of how CD4+ T cells contact their allo-pMHC ligands has clinical 
implications, especially in the area of allopeptide-induced tolerance strategies. Both direct and 
indirect allorecognition play an integral role in graft rejection, with the former dominating acute 
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rejection and the latter mediating chronic rejection. Direct allorecognition involves T cells 
contacting allogeneic MHC molecules, while indirect recognition is a response to syngeneic 
MHC molecules presenting allostimulatory peptides such as those derived from the allogeneic 
MHC (20). Strategies to achieve graft tolerance target both allorecognition pathways. 
Intrathymic injection of allostimulatory antigens - including MHC-derived peptides, soluble 
antigen, and cells - prevented rejection, possibly due to elimination of alloreactive T cells in the 
thymus and/or an increase of regulatory T cells (Tregs) (21). Extrathymic inoculation strategies 
also may be promising. For instance, intratracheal injection of donor splenocytes or an MHC-
derived allopeptide promoted the survival of cardiac allografts (22). With the knowledge that 
CD4+ T cell alloreactivity can exhibit the same binding affinity and kinetics as conventional 
recognition, it is likely that allostimulatory antigen injection is a practical way to achieve 
tolerance since excessive amounts of antigen or unconventional injection strategies will not be 
needed to achieve tolerance. And, viral- and bacterial-specific T cells may not be stimulated 
since our work with LLO118 and 1G5.1 shows peptide allorecognition is not molecular mimicry 
of cognate peptides, allowing for a tolerance strategy that is specific. Additionally, the use of allo 
APLs to induce tolerance has been probed. Two APLs of a peptide derived from the HLA 
molecule DR1 were generated and shown to antagonize the T cell response to wild-type peptide 
presented by DR11, an example of a way to modulate indirect alloreactivity (23). The highly 
allopeptide-specific CD4+ T cell response shown by us and by other labs strengthens the idea 
that allo APLs represent a promising therapeutic strategy. 
 
The ability to recognize allogeneic pMHC ligands, which T cells do not encounter during thymic 
selection, is fascinating because it may represent fundamental binding properties normally not 
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apparent when selection restricts the T cell repertoire. A related concept supporting this idea is 
that although negative selection is crucial for maintaining self-tolerance, it can hide 
evolutionarily conserved TCR-MHC binding properties (24). Indeed, an analysis of the T cell 
repertoire resulting from fairly normal positive selection but greatly limited negative selection 
revealed that the T cells are significantly more alloreactive (4). As such, our data on CD4+ T cell 
alloreactivity support the idea that peptide specificity and low binding affinity of TCR-pMHC 
interactions are fundamental, conserved characteristics of T cells.  
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Figure 2.1 Identification of an I-Ek-restricted allopeptide for the LLO/I-Ab-specific T cell, 
LLO118 
LLO118 T cells were stimulated overnight with (A) varying concentrations of LLO190-201 plus 
irradiated B6 splenocytes; (B) irradiated B6.K splenocytes with or without 10µg/mL αEk 
antibody (clone 14-4-4S); (C) CHO-Ek cells with or without Ek peptides (left) and varying 
concentrations of Ek #75 peptide plus CHO-Ek cells (right). Supernatant was taken and analyzed 
for IL-2 production by ELISA. Data are compiled from 3 independent experiments each 
performed in triplicate wells (A, C left) or are representative of 2 independent experiments each 
in triplicate (B, C right), shown as mean ± sem.
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Figure 2.1 Identification of an I-Ek-restricted allopeptide for the LLO/I-Ab-specific T cell, 
LLO118 
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Figure 2.2 The T cell 1G5.1, also specific to LLO/I-Ab, is not naturally alloreactive 
1G5.1 T cells were stimulated overnight with (A) varying concentrations of LLO190-201 plus 
irradiated B6 splenocytes and (B) either irradiated B6 splenocytes with or without LLO or CH27 
(H-2k) APCs. Supernatant was taken and assessed for IL-2 production by ELISA. Data are 
representative of 3 independent experiments each done in triplicate wells, mean ± sem.
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Figure 2.2 The T cell 1G5.1, also specific to LLO/I-Ab, is not naturally alloreactive 
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Figure 2.3 Identification of an allopeptide mimic for 1G5.1 
1G5.1 T cells were stimulated overnight with CH27 APCs plus (A) peptide pools containing the 
Hb64-76 epitope as the backbone with groups of 4 amino acids at the P3 position and all 20 amino 
acid options (denoted as “X”) at P5 (top) or X at P3 and groups of 4 amino acids at P5 (bottom); 
(B) peptides containing the Hb64-76 epitope with single amino acid substitutions at P3 or P5; and 
(C) the indicated concentrations of Hb F70. Supernatant was taken and assessed for IL-2 
production by ELISA. Data are representative of 2 independent experiments done in triplicate 
wells, shown as mean ± sem. 
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Figure 2.4 Molecular mimicry cannot explain allopeptide recognition by LLO118 and 
1G5.1 
(A) Comparison of TCR contact sites P2, P3, and P5 between LLO190-201, the cognate peptide of 
both LLO118 and 1G5.1, and kidins22047-62 and Hb F7064-76, the allopeptides of LLO118 and 
1G5.1, respectively. (B) LLO118 and 1G5.1 T cells were stimulated over night with CHO-Ek and 
CH27 APCs, respectively, along with allopeptide APLs with residues at P2, P3, or P5 mutated to 
the corresponding amino acids of LLO. For LLO118, peptides were added at 31.6µM and for 
1G5.1, peptides were added at 1µM. Supernatant was taken and analyzed for IL-2 production by 
ELISA. (C) LLO118 and 1G5.1 T cells were stimulated overnight with irradiated B6 splenocytes 
plus LLO APLs with the P2, P3, or P5 residues mutated to the corresponding amino acids of 
kidins220 (for LLO118 stimulation, 0.1µM) or Hb F70 (for 1G5.1 stimulation, 31.6µM). 
Supernatant was taken and analyzed for IL-2 production by ELISA. Data are representative of 2 
independent experiments done in triplicate wells and depicted as mean ± sem.
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Figure 2.4 Molecular mimicry cannot explain allopeptide recognition by LLO118 and 
1G5.1
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Figure 2.5 LLO118 and 1G5.1 exhibit a high degree of peptide specificity for both 
alloreactivity and conventional recognition  
LLO118 and 1G5.1 T cells were stimulated overnight with CHO-Ek cells + kidins220 APLs and 
CH27 cells plus Hb F70 APLs, respectively, at the indicated concentrations (top). LLO118 and 
1G5.1 T cells were also stimulated overnight with irradiated B6 splenocytes plus LLO APLs at 
the indicated concentrations (bottom). The specific amino acid substitutions at P2, P3, or P5 for 
the peptide APLs are depicted. Supernatant was taken and assayed for IL-2 by ELISA. Data are 
representative of 2 independent experiments and presented as mean ± sem.
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Figure 2.5 LLO118 and 1G5.1 exhibit a high degree of peptide specificity for both 
alloreactivity and conventional recognition  
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Figure 2.6 The alloreactive T cell repertoire is expanded by the addition of peptide 
mimotope pools and exhibits a high degree of specificity in peptide mimotope recognition 
(A) A panel of non-alloreactive, CD4+ T cell hybrids was cultured for 24 h with irradiated B6.K 
(H-2k) or B6.P (H-2p) splenocytes with or without 200µM of the EKX or EPX peptide pool, 
respectively. The EKX pool consists of canonical I-Ek MHC binding residues along with all 20 
amino acid options at the TCR contact positions P2, P3, P5, and P8 (amino acid sequence of 
GKKVIXXFXEGXK, with “X” denoting all 20 amino acid options), while the EPX pool has 
peptides with canonical I-Ep MHC anchor residues and unrestricted amino acid usage at P2, P3, 
P5, and P8 (GKKVIXXSXGSXS). Supernatant was taken and assessed for IL-2 by ELISA. 
Results are depicted as means from 3 independent experiments each done in triplicate wells. (B) 
T cell hybrids 4C9 and 1A10 were analyzed for allopeptide specificity. T cells were stimulated 
overnight with CHO-Ek APCs with different concentrations of I-Ek peptide mimotopes (black 
line) or mimotope APLs (grey lines) containing single amino acid substitutions at P3 or P5. 
Supernatant was taken and assessed for IL-2 production by ELISA. Data are representative of 3 
independent experiments each done in triplicate wells and shown as mean ± sem.
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Figure 2.6 The alloreactive T cell repertoire is expanded by the addition of peptide 
mimotope pools and exhibits a high degree of specificity in peptide mimotope recognition   
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Figure 2.7 LLO118 binds its alloligand and cognate ligand with similar kinetics and affinity  
(A) Sample sensorgrams of scLLO118 binding to LLO/I-Ab (cognate ligand) and kidins220/I-Ek 
(alloligand). A concentration series of scLLO118 (40, 16, 8, 4, 2 µM for cognate and 40, 10, 2.5 
µM for allo) was flown over pMHC bound to a Biacore CM5 chip. (B) Equilibrium binding 
analysis of scLLO118 to its cognate (left) and allo (right) ligands was performed with linear 
Scatchard plots shown in the insets that confirm a 1:1 binding. Graphs shown are representative 
of 3-5 experiments. 
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Figure 2.7 LLO118 binds its alloligand and cognate ligand with similar kinetics and affinity  
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Table 2.1 Kinetic values obtained by surface plasmon resonance for LLO118 binding to its 
cognate and allostimulatory ligands 
On-rate, off-rate, and binding affinities obtained from surface plasmon resonance are presented 
as means ± SEM combined from 3-5 experiments.  
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Table 2.1 Kinetic values obtained by surface plasmon resonance for LLO118 binding to its 
cognate and allostimulatory ligands  
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Methods 
 
Generation of CD4+ T cell hybrids 
B6 TCR Cα+/- mice and B6 TCR fixed β Cα+/- mice (β chain from 2.102 or 3.L2 TCR) were 
immunized in the footpads with 10 µM LLO190-201 emulsified with complete Freund’s adjuvant 
(CFA). 7 days later, popliteal lymph node cells were taken and fused with BW5147 TCRα-β- 
cells. Subcloning was performed by limiting dilution. TCR of the T cell hybrids was identified 
by DNA sequencing, with only one TCR expressed in each hybrid due to heterozygosity of the 
TCRα constant region loci. 
  
IL-2 ELISA 
1 x 105 T cells were cultured in 96-well plates with 1 x 105 CH27 APCs, 1 x 105 CHO APCs 
transfected with I-Ek (25) or 1 x 106 irradiated splenocytes along with any indicated peptides for 
24 h. Supernatant was transferred to Immulon 2 HB plates (Thermo Scientific) pre-incubated 
with anti-IL-2 antibody (Bio X Cell). Biotinylated anti-IL-2 antibody (BioLegend) was used to 
detect IL-2, followed by streptavidin-conjugated horseradish peroxidase (Southern Biotech) and 
1-step Ultra TMB-ELISA substrate (Thermo Scientific). 2M sulfuric acid was used to stop the 
reaction, with absorbance values read at 450 nm. 
 
Peptide pools 
Peptides were synthesized by Fmoc chemistry on a Rainin Symphony/Multiplex multiple peptide 
synthesizer (Protein Technologies). Peptide pools were generated by the addition of multiple 
amino acids at the P2, P3, P5, and/or P8 positions during synthesis. Individual peptides were 
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purified by reverse phase HPLC on a C18 column (Vydac), and peptide composition and purity 
were confirmed by MALDI mass spectrometry (Washington University Mass Spectrometry 
Facility). All peptides were sterilized through .22 µM filtration. 
 
Surface plasmon resonance 
The scLLO118 TCR construct was cloned and provided by Steve Persaud (26). scLLO118 
protein was produced in Escherichia coli inclusion bodies, combined and refolded in a guanidine 
hydrochloride based buffer, and purified by size exclusion chromatography. LLO covalently 
linked to I-Ab was produced in S2 cells and purified from the supernatant using the histidine tag 
on the MHC and nickel affinity chromatography (27). I-Ek dimer was produced in S2 cells and 
purified with protein A, with peptide exchanged conducted to add the peptide to the MHC (9). 
pMHC complexes were amine-coupled, either directionally attached using neutravidin-biotin 
interactions (LLO/I-Ab and control gp250/I-Ek) or not (kidins220/I-Ek dimer and control Hb/I-Ek 
dimer), to a Biacore CM5 chip. A concentration series of scLLO118 was flowed over the chip 
until equilibrium was reached, using a Biacore 2000 surface plasmon resonance instrument. 
Control sensorgrams were subtracted from experimental sensorgrams to eliminate non-specific 
binding and fitted to a 1:1 Langmuir binding model using BiaEval version 4.1 (Biacore AB) to 
obtain measurements of association and dissociation as well as affinity.  
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CHAPTER III 
 
The ability to rearrange dual TCR T cells contributes to efficient positive selection of T 
cells and to alloreactivity through increased flexibility in peptide recognition 
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Introduction 
 
Gene rearrangement of the TCRα and TCRβ chains generates T cells with receptors that 
specifically and sensitively recognize self and foreign pMHC ligands to appropriately navigate 
development and mediate immune responses (1). Although the TCRβ chain rearranges under 
tight allelic exclusion and ceases when an in-frame product is made and expressed, TCRα chain 
recombination does not exhibit allelic exclusion, rearranging simultaneously and iteratively on 
both alleles until positively selecting signals are received through the TCR (2-5). The majority of 
thymocytes die from an inability to rearrange a TCR that can mediate positive selection (6-9). 
Iterative revision of TCRα has been demonstrated to be important for efficient positive selection 
of T cells (10). However, the effect of simultaneous TCRα rearrangement on thymocyte selection 
is unclear. The lack of allelic exclusion for TCRα results in thymocytes and peripheral T cells 
with 2 in-frame rearrangements of TCRα (3, 11), and 1-10% mature T cells with dual TCR 
expression on the surface (12-14). In dual TCR T cells, each TCRα chain pairs with the same β 
chain, giving the cell 2 distinct pMHC ligand specificities (15-17). Many questions remain 
regarding the impact of these cells in the periphery.   
 
Dual TCRs in developing thymocytes provide an unusual lessening of the stringent requirements 
for thymic selection. One TCR can successfully mediate positive selection, enabling the presence 
of a secondary TCR that does not participate in positive selection (15, 16, 18). Expression of 
secondary TCRs can also factor importantly during negative selection, masking autoreactive 
TCRs from deletion (19). The contribution of naturally-arising dual TCR T cells to the 
autoreactive T cell repertoire has been suggested by studies of diabetes in NOD mice (20). The 
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potential for TCRs to be exempted from the stringent requirements of thymic selection prompted 
our lab in previous studies to investigate dual TCR T cells in alloreactivity. Alloreactive 
responses were examined in mice genetically lacking dual TCR T cells (TCRα+/-, heterozygous 
for a mutation in the T cell receptor α chain constant region that disrupts formation of a 
functional TCRα chain). Our lab found that dual TCR T cells constitute over 40% of the 
response to allogeneic stimuli, a disproportionate contribution since they make up about 10% of 
the T cell repertoire (16). The impact of secondary TCRs in pathologic alloreactivity was also 
demonstrated in patients developing acute GVHD following allogeneic hematopoietic stem cell 
transplantation. In these patients, dual TCR T cells were expanded, activated, and responded 
preferentially to mismatched alloantigens (21).  
 
The observed potential for atypical or unwanted TCR specificities harbored by dual TCR T cells 
suggests that simultaneous rearrangement of TCRα loci must present a significant benefit in 
thymocyte development to counteract the detrimental effects. We hypothesize that secondary 
TCRα rearrangements improve efficiency of DP thymocyte positive selection but result in an 
increase in the naive autoreactive and alloreactive T cell repertoire. To address this, we examined 
thymocyte development and antigen reactivity in TCRα+/- mice. Mice unable to produce 
secondary TCRs demonstrated decreased positive selection, providing a novel demonstration of 
their importance to effective thymocyte development. While this did not broadly impact 
peripheral T cell numbers or TCRVα and TCRJα gene segment use, TCRα+/- mice had 
diminished binding to autopeptide-MHC and allopeptide-MHC tetramers but not to foreign 
antigen. Decreased in vivo alloreactivity was also seen with TCRα+/- T cells. Analysis of binding 
to APLs of an allostimulatory peptide showed that the presence of secondary TCRs enabled 
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flexibility in recognition of pMHC ligands, providing a mechanism for the significant 
contribution of secondary TCRs to the responses to atypical ligands such as allogeneic or 
autologous pMHC. 
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Results 
 
Secondary TCRα rearrangements enable efficient positive selection 
 
The effects of simultaneous TCRα rearrangement on thymocyte development were evaluated by 
analyzing thymus cellularity and populations in TCRα+/- mice, heterozygous for a mutation in the 
TCRα constant region that disrupts formation of a functional TCRα chain (4). Thymi from B6 
and TCRα+/- mice had similar total number of cells (Fig. 3.1A). There were comparable 
percentages of immature DN (8.8+1.5% vs. 7.6+2.0%) and DP (70.1+3.0% vs. 76.4+3.6%) cells, 
though TCRα+/- thymi had significantly decreased percentages of mature SP cells (14.7+2.2%) 
compared to B6 (19.7+2.5%) (Fig. 3.1B, C). Further examination revealed that TCRα+/- mice 
had significantly reduced percentages of post-selection CD3high thymocytes (8.7+0.6%) 
compared to B6 (13.3+0.7%) (Fig. 3.1D, E). This specific decrease of post-positive selection 
thymocytes implies that secondary TCRα rearrangements are important for efficient thymic 
selection. Co-transfer studies of congenically marked B6 and TCRα+/- cells were performed to 
attribute the deficiency of generating mature SP thymocytes to a cell-intrinsic defect. Pre-
selection CD53- cells from B6.Ly5.1 and TCRα+/-.Thy1.1 thymocytes were mixed at a 1:1 ratio 
and intra-thymically injected into recipient B6 mice. Transferred cells were analyzed 7 days 
post-injection by flow cytometry. The ratio of B6.Ly5.1/TCRα+/-.Thy1.1 among total thymocytes 
was 1.36+0.11, similar to the pre-injection ratio. However, examination of post-selection CD3high 
thymocytes revealed a significant skewing toward B6.Ly5.1 cells (1.86+0.15 ratio), suggesting 
that the inability to perform simultaneous TCRα rearrangements impaired the ability of 
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thymocytes to mature. Comparison of B6.Ly5.1 and TCRα+/-.Thy1.1 thymocyte development 
within individual thymi underscores this observation (Fig. 3.2A-C). 
 
To determine whether the deficiency in generating mature, post-positive selection thymocytes in 
B6.TCRα+/- mice as described above could be explained by a survival defect, we analyzed 
thymocyte viability. B6 and B6.TCRα+/- thymocytes were cultured in vitro for 6 days and stained 
for Annexin V and 7-AAD. Percentages of live cells in culture were similar between B6 and 
TCRα+/- (Fig. 3.3A). In addition, staining of thymocytes ex vivo produced the same conclusion 
(Fig. 3.3B). Our results indicate that the competitive advantage of secondary TCR-sufficient 
thymocytes was not due to a difference in viability.   
 
We reasoned that positive selection would be the most critical window for the influence of 
secondary TCRα chains, as it is estimated that pre-selection DP thymocytes have an average 
lifespan of only approximately 60 h during which they must form a functional TCR to mediate 
positive selection and continue development (9). To examine positive selection kinetics, we 
injected B6 and TCRα+/- mice with a pulse dose of BrdU and evaluated subsequent development 
of labeled thymocytes. There was no difference in the percentage of thymocytes (predominantly 
DN thymocytes) that incorporated BrdU (Fig. 3.4A). However, over the following 96 h, pulsed 
TCRα+/- thymocytes demonstrated a deficient progression to a post-selection CD3high phenotype 
(18.7+2.2%) compared to B6 (27.1+1.8%) (Fig. 3.4B).  
 
Absence of secondary TCRα rearrangements eliminates certain TCR specificities  
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The contribution of secondary TCRα chains in mediating thymocyte development suggests that 
their absence could affect the peripheral T cell repertoire. The lack of secondary TCRα 
rearrangements did not affect peripheral T cell numbers in the spleen (Fig. 3.5A) or CD4 and 
CD8 subsets (Fig. 3.5B). To examine potential skewing of the TCR repertoire, TRAV and TRAJ 
gene segment use was analyzed by TCRα cDNA sequence analysis of peripheral T cells from 3 
B6 and 3 TCRα+/- mice. Analysis of 123,655 B6 and 104,434 TCRα+/- TCRα transcripts revealed 
similar TRAV (Fig. 3.5C) and TRAJ (Fig. 3.5D) gene segment use, indicating that the absence of 
secondary TCRs does not broadly affect the T cell repertoire. For a more focused examination, 
we compared TCRα sequences of TCRVα2+ (TRAV14) T cells from TCRα+/- mice with 
TRAV14+ TCRα transcripts of dual TCR T cells (TCRVα2+ and TCRVα3/8/11+) from B6 mice. 
This enabled direct comparison of TCRα repertoire composition in the presence or absence of 
secondary TCRs. From 3 independent TRAV14+ TCRα transcript libraries for each mouse strain, 
we analyzed 141,353 B6 TRAV14+ TCRα sequences and 148,228 TCRα+/- TRAV14+ TCRα 
sequences, yielding 13,646 and 14,002 unique CDR3α sequences respectively. There was no 
difference between TCRα+/- and dual TCR B6 TRAV14+ TCRα sequences in CDR3 length (Fig. 
3.6A), amino acid composition (Fig. 3.6B), and TRAJ gene segment use (Fig. 3.6C).  
 
Despite the similarities seen thus far, the majority of unique TRAV14+ CDR3α sequences were 
different between B6 and TCRα+/- (66.2% of B6 repertoire), indicating a potential for significant 
differences between the 2 repertoires (Fig. 3.6D). It is possible that the impact of secondary 
TCRα rearrangements would be more subtle and reflected in the presence or absence of specific 
TCRα sequences that might normally be negatively selected against if present as the only TCR. 
Interestingly, CDR3 sequences unique to the TCRα+/- TRAV14+ repertoire were all low 
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abundance species each representing less than 0.1% of the TRAV14+ repertoire, suggesting that 
their absence in dual TCR B6 T cells is stochastic. In contrast, sequences unique to the B6 dual 
TCR T cells were of relatively high abundance (> 0.1% of the TRAV14+ repertoire) (Fig. 3.6E). 
We think this implies that their exclusion from the TCRα+/- repertoire is active, likely owing to a 
difference in the stringency of thymic selection.  
 
Secondary TCRs contribute to naive alloreactive and autoreactive repertoires  
 
Findings from TCRα repertoire analysis suggest that exclusion of distinct sequences in TCRα+/- 
mice could manifest as a differential ability of the naive T cell repertoire to respond to antigens. 
We measured the reactivity of naive B6 and TCRα+/- T cells using class II pMHC tetramers to 
estimate the frequency of antigen-specific T cells (22). We generated I-Ek tetramers loaded with 
either CD22654-666 or transferrin receptor (TFR)231-244 peptides. These peptides were previously 
identified by mass spectrometry of endogenous peptides eluted from I-Ek molecules and known 
to stimulate I-Ek-alloreactive T cells generated from B6 mice (23). T cells were labeled with 
alloantigen pMHC tetramers, enriched by magnetic bead selection, and identified by flow 
cytometry (Fig. 3.7A). CD22/I-Ek and TFR/I-Ek tetramer positive and negative cells from B6 
mice were sorted by flow cytometry and assessed for response to CD22 and TFR peptides. 
Tetramer positive populations responded to their peptide, whereas the tetramer negative cells did 
not (Fig. 3.7B), demonstrating the efficiency of our pMHC tetramer labeling. TCRα+/- mice had 
a consistently decreased frequency of response to individual allogeneic pMHC complexes. The 
frequency of TCRα+/- T cells recognizing the TFR/I-Ek tetramer was significantly decreased 
compared to that of B6 T cells (8.6+0.9 vs.19.9+4.7 cells/105 T cells, respectively) (Fig. 3.8A). 
	   62	  
CD22/I-Ek tetramer binding yielded a similar trend, though not significant (72.6+8.6 TCRα+/- vs. 
115.9+18.0 B6 cells/105 T cells) (Fig. 3.8B). There was no significant difference between B6 
and TCRα+/- T cell response to a minor histocompatibility antigen, Eα52-68 presented by self-
MHC I-Ab (4.3+1.0 vs. 3.1+0.9 cells/105 T cells, respectively) (Fig. 3.8C).  
 
Consistent with our hypothesis proposing that secondary TCRα rearrangements contribute 
specifically to the recognition of atypical ligands, TCRα+/- mice also had reduced frequencies of 
naive CD4+ T cells recognizing the autoantigen myelin oligodendrocyte glycoprotein (MOG)38-49 
presented by I-Ab (8.6+2.5 cells/105 T cells) as compared to B6 (28.3+9.3 cells/105 T cells) (Fig. 
3.9A). Conversely, recognition of I-Ab tetramer presenting a foreign antigen, lymphocytic 
choriomeningitis virus (LCMV)66-77 was comparable between B6 and TCRα+/- CD4+ T cells 
(4.7+2.3 vs. 5.8+2.5 cells/105 T cells, respectively) (Fig. 3.9B). These results demonstrate 
specific contribution of secondary TCRα rearrangements to the alloreactive and autoreactive T 
cell repertoires.  
 
Secondary TCRs increase early during in vivo alloreactivity  
 
To evaluate the contribution of secondary TCRs during in vivo alloreactivity, we used an MHC-
mismatched model of GVHD. B6.Ly5.1 and TCRα+/-.Thy1.1 T cells were mixed 1:1 (Fig. 
3.10A), pulsed with CFSE, and injected into lethally irradiated B6.K recipient mice. Expansion 
of transferred T cells was assessed by flow cytometry 24 h after transfer. While the 2 cell 
populations were transferred at equal numbers (ratio TCRα+/-/B6 T cells = 0.99+0.07%), 
recovery of TCRα+/- cells was decreased after 24 h (ratio TCRα+/-/B6 T cells = 0.41+0.09%) 
	   63	  
(Fig. 3.10B). The difference was due to a decreased proliferative response by the TCRα+/- cells 
as evidenced by CFSE dilution (Fig. 3.10C, D). The diminished response of TCRα+/- T cells 
early after allogeneic stimulation in vivo illustrates a functional consequence of the decreased 
frequency of alloreactive T cells in the absence of secondary TCRα rearrangements and 
underscores the potential importance of dual TCR T cells in driving early pathologic alloreactive 
responses.  
 
The presence of secondary TCRs enables flexibility in recognition of allogeneic ligands 
 
The contribution of secondary TCRs to the alloreactive and autoreactive T cell repertoire has 
multiple possible mechanistic explanations. One is that elimination of secondary TCRα 
rearrangements results in a decreased number of TCRs, which reduces the probability of 
recognizing a specific antigen. However, secondary TCRs comprise less than 10% of the T cell 
repertoire, and our data indicate that they encompass 40-50% of the alloreactive repertoire and 
possibly as much as 70% of the autoreactive repertoire, but do not affect recognition of 
conventional foreign antigens. This specific and disproportionate effect suggests that it is not 
simple stochastic addition of antigen specificities to the repertoire by secondary TCRs, but rather 
a unique functional property of secondary TCRs.  
 
To investigate this, we compared functional responses of CD22/I-Ek tetramer binding T cells 
from B6 and TCRα+/- mice to APLs. Tetramer positive cells from naive mice were sorted by flow 
cytometry and stimulated with the wild-type CD22 peptide or CD22 APLs containing single 
amino acid substitutions at TCR contact sites (P2 and P5). Responses were assessed by 
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measurement of IFNγ production after 24 h culture. IFNγ production to either non-specific 
stimulation, phorbol 12-myristate 13-acetate (PMA), or wild-type CD22 peptide was similar 
between the 2 cell types (Fig. 3.11A). However, B6 cells responded to APLs with mutations at 
either the P2 or P5 positions while TCRα+/- cells did not (Fig. 3.11A, B). These data indicate that 
the contribution of dual TCR T cells to recognition of atypical ligands results from an unusual 
flexibility in ligand recognition. 
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Discussion 
 
The existence of a minority of T cells expressing 2 TCRs in mice and humans has been 
recognized for some time (13), though the biological significance of these cells has not been well 
understood. Studies of transgenic TCR systems demonstrated that secondary TCRα 
recombination enables TCRs with unwanted reactivities to escape thymic selection and emigrate 
to the periphery (17, 19). We wondered if there are any potential benefits of simultaneous TCRα 
chain rearrangement in T cell development that would offset its detrimental impacts on the 
peripheral T cell repertoire. To address this, we used mice genetically deficient for secondary 
TCRα rearrangements to define their role in thymocyte development and in the generation of the 
T cell repertoire. 
 
Analysis of thymocyte development in TCRα+/- mice demonstrated defective production of 
mature post-positive selection CD3high SP cells, supporting the notion that simultaneous TCRα 
rearrangements occur to maximize the efficiency of mature T cell production from thymocytes 
that had successfully mediated β-selection. Our results demonstrate that secondary TCRα 
rearrangements are quantitatively important for thymocyte development, though we cannot 
ascribe the relative importance of their effects on mediating positive selection versus masking 
thymocytes with autoreactive TCRs from negative selection. This will require further 
investigation in systems where these questions can be separated. The elimination of secondary 
TCRα rearrangements did not broadly affect the peripheral T cell repertoire, either in the number 
of T cells, or in the general use of TCRVα and TCRJα gene segments. A more focused 
comparison of TRAV14 TCR transcripts between T cells lacking secondary TCRα 
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rearrangements and T cells with dual TCR expression similarly revealed no differences in 
general TCR properties. However, dual TCR T cells had numerous high abundance CDR3 
sequences that were absent among cells lacking secondary TCRα chains. The reciprocal was not 
true, indicating that the presence of these unique TCRα sequences depended on secondary TCRα 
rearrangements. These data support our hypothesis that secondary TCRs have a unique 
contribution to the peripheral T cell repertoire.  
 
We hypothesize that secondary TCRα rearrangements increase the T cell repertoire for atypical 
self and allogeneic pMHC ligands due to the effects of dual TCR expression on the requirements 
for thymic selection. Indeed, our tetramer binding data revealed that secondary TCRs contribute 
significantly and specifically in responses to peptides involved in autoimmunity and 
alloreactivity, but not to cognate ligands. Mechanistically, the presence of secondary TCRs may 
prevent cells from becoming negatively selected when exposed to autoantigens during T cell 
development as well as provides TCRs that do not undergo positive selection to self MHC and 
may have more flexibility in binding non-self MHC. The decreased response of CD4+ T cells 
from TCRα+/- mice to MOG/I-Ab tetramers was somewhat unexpected given a previous study 
reporting no impact on EAE disease outcome in mice lacking secondary TCRs (20). In that 
study, the effect of secondary TCRs was measured following immunization with antigen and 
adjuvant as compared to our interrogation of the naive T cell repertoire. Given that the NOD 
diabetes model, which does not rely on adjuvants, also indicated a role for dual TCR T cells (20), 
it seems that secondary TCRs may be important contributors to autoimmunity under 
physiological conditions. In addition to pathogenic autoreactive T cells, Tregs also function by 
recognizing self. Interestingly, a report indicating that a majority of Tregs in humans express 2 
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TCRs (24) highlights the potential for dual TCR T cells to recognize self-pMHC in a high 
affinity capacity. It is unclear whether these dual TCR Tregs are thymically derived or result 
from peripheral conversion. Further studies are required to understand how recognition of self-
pMHC may direct Treg lineage commitment or conversion. An additional unexpected finding is 
the lack of a difference between T cells from B6 and TCRα+/- mice in recognition of the Eα/IAb, 
which we consider a minor histocompatibility antigen between B6 and B6.K mice. This differs 
from previous findings from our lab using the human HA-1/HLA-A*02:01 minor 
histocompatibility antigen model (21). It is possible that this is a result of a nuanced but 
important difference between the systems - while the HA-1 antigen is a difference of a single 
amino acid between the 2 polymorphisms, B6 mice do not express the I-Eα molecule at all, 
which may make the response more similar to a foreign antigen rather than an alloantigen. 
 
The potential for secondary TCRs to participate in pathogenic alloresponses has been 
demonstrated by previous studies examining dual TCR T cells in mouse models and patients 
with GVHD (16, 21). Our data here demonstrating decreased proliferative potential of TCRα+/- T 
cells during in vivo alloreactivity provide insight into the mechanism by which dual TCR T cells 
contribute to alloresponses. Furthermore, we hypothesize that secondary TCRs are specifically 
important in alloreactivity as well as autoimmunity due to differential properties for their 
interaction with pMHC ligands derived from their uniquely relaxed constraints of thymic 
selection. It has been demonstrated that negative selection is important for eliminating 
crossreactive TCRs (25), and thus secondary TCRs masked from negative selection may be more 
crossreactive. This is supported by our data demonstrating the strikingly reduced stringency of 
recognition of an allopeptide by secondary TCRs (Fig. 3.11). While our data do not question the 
	   68	  
importance of T cell recognition of peptides in alloreactivity, shown by numerous studies 
demonstrating integral TCR interactions with the allopeptide (23, 26) as well as our data in 
Chapter II, it does indicate a potential mechanism for the increased propensity for dual TCR T 
cells to respond to specific pMHC ligands.  
 
In summary, we show that efficient thymocyte development requires simultaneous 
rearrangement of both TCRα loci. However, this comes at a cost, with resulting secondary TCRs 
having an increased ability to respond to self and allogeneic pMHC. Our results highlight a 
hitherto underappreciated role of dual TCR-expressing T cells in the development of the T cell 
repertoire and suggest that therapeutic strategies for combatting autoimmune diseases or 
transplant rejection and GVHD take into account the significant contribution of these uniquely 
powerful T cells.
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Figure 3.1 Thymic generation of mature T cells is deficient in the absence of secondary 
TCRα rearrangements 
(A) Comparison of numbers of thymocytes in 6 week old B6 and TCRα+/- mice. Each point 
represents a single mouse, n = 17, 4 independent experiments, mean ± sem, Mann-Whitney test. 
(B - E) The effect of secondary TCRα rearrangements on T cell development was examined by 
comparing thymi of B6 and TCRα+/- mice by flow cytometry, n = 10, 3 independent experiments. 
(B) Representative plots of CD4 and CD8 labeling of thymocytes from individual mice. (C) 
Percentages of mature CD4+ or CD8+ SP, CD4+CD8+ DP, or CD4-CD8- DN thymocytes. Each 
point represents a single thymus, mean ± sem, Mann-Whitney test. (D) Representative plots of 
CD3 and CD69 labeling of thymocytes from individual mice. (E) Percentages of post-positive 
selection CD3high thymocytes. Each point represents a single thymus, mean ± sem, Mann-
Whitney test. 
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Figure 3.1 Thymic generation of mature T cells is deficient in the absence of secondary 
TCRα rearrangements 
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Figure 3.2 The deficiency in generating mature SP thymocytes is a cell-intrinsic defect of 
secondary TCRα rearrangements 
Pre-selection thymocytes from congenically-marked B6.Ly5.1 and TCRα+/-.Thy1.1 mice were 
enriched by magnetic bead selection, combined at a 1:1 ratio, and 107 cells transferred by 
intrathymic injection into B6 mice to examine development (n = 8, 3 independent experiments). 
Transferred cells were detected 7 d after injection by flow cytometric analysis of thymocytes. 
(A) Representative plot with congenically-marked transferred cells expressed as percentage of 
total thymocytes. (B) Ratio of B6.Ly5.1 to B6.TCRα+/-.Thy1.1 cells among total thymocytes and 
post-selection CD3high thymocytes. Mean ± sem, paired ratio t test. (C) Development of post-
selection CD3high thymocytes was compared between B6.Ly5.1 and TCRα+/-.Thy1.1 thymocytes 
in individual mice. Transferred populations in a single mouse are linked by the line between 
points, paired ratio t test. 
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Figure 3.3 The deficiency of generating mature T cells in mice lacking secondary TCRα 
rearrangements is not attributable to decreased cell survival 
Thymocyte survival was compared between thymocytes from 6 wk old B6 and TCRα+/- mice by 
labeling for CD4, CD8, Annexin V and staining with 7-AAD to detect live (Annexin V and 7-
AAD negative) thymocyte populations. (A) Thymocytes were cultured in vitro at 107 
thymocytes/ml and sampled at the indicated time points. Points are mean + sem of 6 thymic 
cultures from 3 independent experiments, data analyzed by ANOVA. (B) Thymocytes were 
taken from mice and analyzed directly ex vivo. Each point represents one mouse from three 
independent experiments. Data are shown as mean + sem, analyzed by Mann-Whitney test. 
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Figure 3.4 Lacking secondary TCRα rearrangements impairs efficient positive selection  
Intra-peritoneal (i.p.) administration of BrdU (1.6 mg) was done on d 0. (A) Thymocyte BrdU 
incorporation was evaluated at 24 h post-injection (n = 6, 3 independent experiments, mean + 
sem, Mann-Whitney test). (B) Thymocyte development in BrdU-pulsed B6 and B6.TCRα+/- mice 
was compared by analyzing development of CD3high post-positive selection thymocytes by flow 
cytometry at 24 h, 48 h, and 96 h post-BrdU injection. Mean + sem of 6 mice per group in 3 
independent experiments, Mann-Whitney test. 
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Figure 3.5 Elimination of secondary TCRα rearrangements does not broadly alter the 
peripheral T cell repertoire  
(A) Comparison of numbers of T cells in the spleens of 6 week old B6 and TCRα+/- mice. Each 
point represents a single mouse, n = 6, 3 independent experiments, mean + sem, Mann-Whitney 
test. (B) Comparison of CD4+ and CD8+ T cell composition, measured by flow cytometry of 
splenocytes. Mean + sem of 6 mice from 3 independent experiments, Mann-Whitney test. 
Comparison of (C) TRAV and (D) TRAJ gene segment use by DNA sequence analysis of splenic 
T cells from 6 week old B6 and TCRα+/- mice (3 mice each, 23,877 - 34,995 TCRα sequence 
reads/mouse). Mean + sd for each group, data analyzed by ANOVA.
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Figure 3.6 Lacking secondary TCRα rearrangements results in elimination of specific 
TCRs from the naive T cell repertoire 
TRAV14 T cell receptor libraries were generated from TCRα+/- TCRVα2+ T cells and B6 
TCRVα2+ dual TCR T cells (identified by co-expression of TCRVα3, TCRVα8, and TCRVα11) 
sorted by flow cytometry. Three independent libraries per group were sequenced and generated 
141,353 B6 TRAV14+ TCRα sequences and 148,228 TCRα+/- TRAV14+ TCRα sequences. 
Analysis of (A) CDR3 length, (B) CDR3 amino acid composition, and (C) TRAJ gene segment 
use was compared between the 2 groups. (D) 23,039 total unique sequences were obtained and 
divided among the groups as indicated. (E) The 5 most abundant TRAV14 CDR3 sequences 
unique to each population are shown with corresponding frequencies.
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Figure 3.6 Lacking secondary TCRα rearrangements results in elimination of specific 
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Figure 3.7 Allopeptide-MHC tetramers specifically detect alloreactive T cell populations  
Splenocytes, axillary, inguinal, and popliteal lymph nodes were collected from B6 and TCRα+/- 
mice, incubated with PE-labeled allogeneic pMHC tetramers, enriched by magnetic selection 
using anti-PE beads, and singlet T cells were analyzed by flow cytometry. (A) Representative B6 
mouse sample labeled with TFR/I-Ek is shown. (B) Reactivity of pMHC tetramer-labeled cells 
was assessed by sorting tetramer-positive and tetramer-negative T cells by flow cytometry and 
measuring IFN-γ production following 18 h culture with CHO-Ek cells and 10 µM CD22 or 50 
µM TFR peptide. IFN-γ production was measured by intracellular cytokine staining, with percent 
of IFN-γ+ cells indicated. Data are representative examples of 3 independent experiments. 
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Figure 3.8 Secondary TCRα rearrangements increase the alloreactive T cell repertoire as 
measured by tetramer staining  
Splenocytes, axillary, inguinal, and popliteal lymph nodes were collected from B6 and TCRα+/- 
mice, incubated with APC- or PE-labeled allogeneic pMHC tetramers, enriched by magnetic 
selection using anti-APC or anti-PE beads, and singlet T cells were analyzed by flow cytometry. 
The frequency of alloantigen-reactive T cells bound to the (A) TFR/I-Ek, (B) CD22/I-Ek, and (C) 
Eα/I-Ab tetramers was calculated as the number of tetramer+ cells/105 T cells collected from each 
mouse. Data points are individual mice (n = 8-11) from 4 independent experiments, mean + sem, 
Mann-Whitney test.
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Figure 3.9 Secondary TCRα rearrangements increase the frequency of T cells responsive to 
an autoantigen but not to cognate pMHC  
Splenocytes, axillary, inguinal, and popliteal lymph nodes were collected from B6 and TCRα+/- 
mice, incubated with APC- or PE-labeled allogeneic pMHC tetramers, enriched by magnetic 
selection using anti-APC or anti-PE beads, and singlet T cells were analyzed by flow cytometry. 
The frequency of (A) autoantigen- and (B) cognate peptide-reactive T cells was calculated as the 
number of tetramer+ cells/105 CD4+ T cells collected from each mouse. Data points are 
individual mice (n = 5-6) from 3 independent experiments, mean + sem, Mann-Whitney test.
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Figure 3.10 Elimination of secondary TCRα rearrangements reduced in vivo T cell 
alloreactivity 
Congenically-marked B6.Ly5.1 and TCRα+/-.Thy1.1 T cells (both H-2b) were mixed at a 1:1 
ratio, pulsed with CFSE, and injected into lethally-irradiated MHC mismatched B6.K (H-2k) 
recipients. (A) Pre-injection cells were labeled for congenic markers to confirm ratio of cells. 
Representative example from 3 independent experiments. (B) Transferred cells were analyzed at 
24 h by flow cytometry of splenocytes. Cells were labeled for congenic markers to examine ratio 
of TCRα+/-.Thy1.1 and B6.Ly5.1 T cells pre-transfer and 24 h post-transfer. Results shown are 
mean + sem of 12 recipient mice from 3 independent experiments, Mann-Whitney test. (C, D) 
Proliferation of transferred T cells was assessed by measuring CFSE dilution at 24 h post-
transfer. (C) Representative CFSE plot of 1 recipient mouse. (D) Percentages of CFSElow, 
divided B6.Ly5.1 and TCRα+/-.Thy1.1 T cells from 12 mice, 3 independent experiments. Data 
shown are mean ± sem, paired t test. 
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Figure 3.11 The presence of T cells with secondary TCRα rearrangements enables more 
flexibility in allopeptide recognition 
CD22/I-Ek alloantigen-reactive T cells were collected from B6 and TCRα+/- mice by tetramer-
labeling, magnetic enrichment, and flow cytometry sorting. T cells were cultured with CHO-Ek 
cells for 24 h, either in the presence of the CD22 peptide or CD22 peptide APLs P2A (H to A 
change at TCR contact P2) and P5S (G to S change at TCR contact P5). PMA (20 ng/ml) and 
ionomycin (1 µM) was used as a positive control. T cell responses were measured by flow 
cytometry with intracellular labeling for IFN-γ production. (A) Representative experiment 
shown. (B) Aggregate data from 3 independent experiments with APL response normalized to 
the response against wild-type CD22 peptide, mean + sem, ANOVA.
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Methods 
 
Mice 
B6, B6.Ly5.1, B6.Thy1.1 and B6.K mice were originally purchased from The Jackson 
Laboratory. TCRα+/- mice, incapable of expressing two TCRα chains due to a targeted disruption 
at the 5’ end of one copy of the TRAC gene, were derived by crossing TRAC-/- B6 mice (4) with 
B6 or B6.Thy.1.1 mice. Mice were bred and housed in specific pathogen-free conditions at 
Washington University Medical Center (St. Louis, MO). All use of laboratory animals was 
approved and performed in accordance with the Washington University Division of Comparative 
Medicine guidelines. 
 
Flow cytometry 
Thymocyte and T cell analyses were performed using anti-CD3 (145-2C11)-PE-Cy7, anti-
CD45.2 (104)-PerCP-Cy5.5, anti-CD90.1 (HIS51)-eFluor 450 (eBioscience), anti-CD69 
(H1.2F3)-PE-Cy7, anti-CD4 (RM4-5)-PerCP, anti-CD8α (53-6.7)-APC-Cy7 (Biolegend), and 
anti-CD45.1 (A20)-APC (BD Biosciences). Non-T cells were excluded by labeling with Pacific 
Blue-labeled anti-B220 (RA3-6B2), anti-CD11b (M1/70), anti-CD11c (N418), and anti-F4/80 
(BM8) (Biolegend). TCRVα2+ and dual TCR T cells were identified among CD3+B220-CD11b-
CD11c-F4/80- splenocytes using anti-TCRVα2 (B20.1)-PE and anti-TCRVα3 (RR3-16)-FITC, 
anti-TCRVα8 (KT50)-FITC, and anti-TCRVα11 (RR8-1)-FITC (BD Biosciences). Samples were 
analyzed using LSR II or LSR Fortessa cytometers (BD Biosciences) with calculated 
compensation, and data were analyzed with FlowJo software (Tree Star).  FACSAria II (BD 
Biosciences) was used for sorting.   
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Thymocyte culture 
Survival was assessed by culturing 107 thymocytes/mL in RPMI 1640 (Life Technologies) 
supplemented with 10% fetal bovine serum (PAA), 2 mM GlutaMAX, and 50 mg/ml gentamycin 
for 6 days. In vitro cultures or freshly isolated thymocytes were labeled for CD4, CD8, Annexin 
V, and 7-AAD (Biolegend), and analyzed by flow cytometry.  
 
Thymocyte transfers 
B6.Ly5.1 and TCRα+/-.Thy1.1 pre-selection thymocyte populations were bead-enriched for 
CD53- cells using anti-CD53 mAb (OX-79, Biolegend) and anti-IgM paramagnetic beads 
(Miltenyi Biotec). Enriched cell populations were mixed at a 1:1 ratio and injected 
intrathymically into sublethally irradiated (5 Gy) B6 recipient mice. Thymi from recipient mice 
were analyzed 7 days post-injection by flow cyomtetry. 
 
BrdU labeling 
Mice were injected intraperitoneally with 1.2 mg BrdU (Sigma) and thymi were harvested at 24, 
48, and 96 h timepoints. Thymocytes were labeled for surface markers, fixed with BD CytoFix 
(BD Biosciences), permeabilized with Permeabilization Wash Buffer (Biolegend), treated with 1 
mL DNase I (Sigma) at 50 U/mL, intracellularly labeled with anti-BrdU (BU20A)-FITC 
(eBioscience), and analyzed by flow cytometry. 
 
TCR repertoire analysis 
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TCRVα2+ T cells and dual TCR T cells were sorted from TCRα+/- and B6 splenocytes, 
respectively, by flow cytometry. TCRα cDNA libraries were generated by PCR (27, 28) and 
sequenced by 250 cycle paired-end sequencing using an Illumina MiSeq at the Washington 
University Genome Sequencing Center. TRAV and TRAJ gene segment use was determined by 
sequence analysis using the International ImMunoGeneTics Information System nucleotide 
sequence database (29). 
 
Tetramer enrichment 
LCMV glycoprotein (GP)66-77 (DIYKGVYQFKSV) / I-Ab (LCMV-Ab tetramer)-APC, mouse 
MHC class II antigen Eα52-68 (ASFEAQGALANIAVDKA) / I-Ab (Eα-Ab tetramer)-APC, and 
MOG38-49 (GWYRSPFSRVVH) / I-Ab (MOG-Ab tetramer)-PE were obtained from the NIH 
Tetramer Core Facility at Emory University (Atlanta, GA). Murine CD22654-666 
(SGQDLHSSGQKLR) / I-Ek (CD22-Ek tetramer)-PE and murine TFR231-244 
(SGKLVHANFGTKKD) / I-Ek (TFR-Ek tetramer)-PE tetramers were generated using soluble I-
Ek produced in E. coli inclusion bodies and refolded with peptide (30). Tetramer enrichment was 
performed according to published protocols (22). Briefly, cells were incubated with tetramer for 
1 h at room temperature, washed, incubated with anti-PE and/or anti-APC conjugated 
microbeads for 30 min at 4°C, and passed over magnetized LS columns for positive selection 
(Miltenyi Biotec). Enriched populations were labeled for surface markers for 20 min. at 4°C and 
analyzed or sorted by flow cytometry. 
 
Intracellular cytokine staining 
	   94	  
T cell antigen-specific responses were assessed by 24 h culture with 105 CHO-Ek cells and 
stimulated with 20 ng/ml PMA and 1 µM ionomycin or 10–50 µM peptide in round-bottom 96-
well plates at 37°C. During the last 4 h of culture, 10 µg/mL Brefeldin A (Sigma-Aldrich) was 
added. Live cells were stained using LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular 
Probes), labeled for surface markers, and intracellularly labeled with anti-IFNγ (XMG1.2)-FITC 
or isotype control (Biolegend). 
 
In vivo alloreactive response 
T cells were enriched from B6.Ly5.1 and TCRα+/-.Thy1.1 spleens using anti-CD4 and anti-CD8 
paramagnetic beads and LS columns (Miltenyi Biotec), mixed 1:1, pulsed with 5 mM CFSE 
(Sigma), and 5–10 x 106 cells were injected through an intra-venous (i.v.) route into lethally 
irradiated (10 Gy) B6.K mice. Splenocytes were harvested at 8 h and 24 h after injection, labeled 
for surface markers, and analyzed by flow cytometry for CFSE dilution. 
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CHAPTER IV 
 
Both positive and negative effects on CD4+ T cell responses result from the addition of a 
second class II MHC molecule, I-Eb 
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Introduction 
 
Humans express three types of class I (HLA-A, HLA-B, and HLA-C) and three class II (HLA-
DP, HLA-DQ, and HLA-DR) MHC molecules, while mice have up to three types of class I (H2-
K, H2-D, and H2-L) and only one or two class II (I-A and I-E in some) MHC molecules (1-3). 
The number of MHC molecules expressed can be viewed as quite low considering the important 
function of the MHC in presenting peptides both in the thymus and in the periphery for T cell 
selection and activation against pathogens, respectively (4). It is a difficult process for 
thymocytes to make it past selection, and positive selection is particularly stringent with 
approximately 90% of thymocytes dying by neglect due to an inability to sufficiently bind 
(pMHC) complexes (5-9). Therefore, it is curious why vertebrates do not express more MHC 
molecules, which would theoretically result in an increase in T cells that successfully make it 
past positive selection. Mathematical modeling suggests that the number of MHC molecules can 
be increased significantly without suffering adverse effects on the ability to mount a response to 
pathogens, with estimates even as high as 1,500 MHC molecules (10, 11). Understanding what 
impact expressing additional MHC molecules would have on immunity is important for 
increasing our knowledge of the factors influencing the nature of the T cell repertoire, which 
ultimately impacts a wide spectrum of immune responses, including the ability to tolerate 
transplantation in addition to reactivity to pathogens and susceptibility to autoimmune disease.  
 
MHC molecules on medullary thymic epithelial cells and bone marrow derived antigen 
presenting cells APCs induce negative selection, deleting T cells containing high affinity TCRs 
to preserve self-tolerance (12). This role implies that increasing the number of MHC molecules 
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may overly restrict the T cell repertoire. Studies that support the substantial effect of negative 
selection on the T cell repertoire include the elimination of approximately 5% of thymocytes by 
a single MHC molecule (13), deletion of the TCR Vβ17-expressing T cell population by I-E 
(14), and the ability of 1-10% of T cells to recognize allogeneic MHC (15-17) which suggests a 
significant portion of T cells would bind to a new MHC encountered in the thymus, possibly too 
strongly. Knowing whether the introduction of additional MHC molecules results in either a net 
gain of positive selection or negative selection effects is integral in understanding the ultimate 
implications on immune responses.  
 
Thus far, there are conflicting reports on whether the expression of additional MHC molecules 
would be beneficial or detrimental to immune responses. MHC heterozygotes were shown to 
have greater pathogen resistance compared to their littermate MHC homozygote mice (18, 19). 
On the other hand, F1 progeny of parents with disparate MHC haplotypes were shown to have 
dampened T cell reactivity in the context of viral infections (20, 21). Studies have also 
approached this issue by adding just one more MHC molecule to the repertoire. The majority of 
reports focused on autoimmunity, with most concluding that expressing more MHC is beneficial. 
Adding I-E expression to mice of different MHC haplotypes protected from diabetes, lupus, 
experimental autoimmune myasthenia gravis, and collagen-induced arthritis (22-28). Yet, it was 
also shown that the addition of I-Eb was detrimental, resulting in enhanced susceptibility to 
autoimmune thyroiditis (29). A viral infection model lent support for negative effects resulting 
from adding a second MHC molecule. Here, the CD4+ T cell response to influenza peptides was 
diminished in mice expressing two I-A molecules compared to one (30).  
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The I-E MHC, which has been a useful tool to add back to the mouse MHC repertoire, is 
puzzling for its disappearance from a substantial population of mouse strains. H-2b, H-2s, H-2f, 
and H-2q haplotype mouse strains and approximately 20% of wild mice do not express I-E (31). 
Studies support the idea that there exists some advantage for losing I-E MHC expression. First, it 
was shown that three distinct mechanisms contribute to the loss of I-E expression. H-2b and H-2s 
haplotype mice have a deletion in the Eα gene, H-2f mice synthesize Eα mRNA of an aberrant 
size, and H-2q mice exhibit a defect in Eα RNA processing and/or mRNA stability (32). Second, 
the deletion in the Eα gene was found to be identical between wild mice and H-2b plus H-2s 
haplotype mice, suggesting the mutation occurred early and disseminated widely throughout the 
mouse species (33-35). However, it does not make sense why some mice still express both I-A 
and I-E class II MHC molecules and are capable of surviving normally if I-E is that harmful. 
Thus, we sought to resolve the important question of what impact does I-E have on immune 
responses. Previous studies have not tested what effect expressing additional MHC would have 
on alloreactivity, a T cell response in which we are particularly interested. And, prior work 
examined the effects of adding MHC on only one disease model (ie. only lupus was studied 
when an I-E molecule comprised of EαdEβb was expressed, or in mice additionally expressing 
EαkEβd, only collagen-induced arthritis was probed). It is unknown whether adding a particular 
MHC exerts distinct effects on different T cell responses. 
 
In our studies, we used B6.E+ mice, which have the monomorphic Eαk transgene thus enabling I-
Eb expression, to address the impact of having one additional class II MHC on a range of 
immune responses. We hypothesized that there would be negative consequences to immune 
responses from adding I-Eb, providing a reason for the limit on the number of MHC molecules 
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expressed. We saw that in alloreactivity, the B6.E+ T cell response was significantly dampened. 
Interestingly, diverse effects of I-Eb were seen when we probed its impact on other types of 
immune responses. In hen egg-white lysozyme (HEL) protein immunization, we found similar 
B6 and B6.E+ T cell responses. In viral infection with LCMV, I-Eb elicited subtle differences in 
CD4+ T cell cytokine production. Finally, in an autoimmune disease model, EAE, expression of 
I-Eb resulted in detrimental consequences. There was significantly enhanced disease in B6.E+ 
mice compared to B6. This was not attributable to greater numbers of pathogenic T cells or 
increased effector cytokine production. Instead, B6.E+ mice had decreased Treg cell percentages 
during EAE, a deficiency related to altered selection mediated by I-Eb. Altogether, the data 
suggest that the limitation on the number of MHC molecules we express may be to prevent 
autoimmunity. 
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Results 
 
The expression of a second class II MHC molecule, I-Eb, alters the naive T cell repertoire 
 
To understand the impact that increasing the number of MHC molecules has on the naive T cell 
repertoire, the thymus populations of B6 and B6.E+ mice were compared. B6 mice express only 
one class II MHC molecule, I-Ab, and do not express I-Eb due to a deletion in the Eα gene, while 
B6.E+ mice have both I-Ab and I-Eb resulting from transgenic expression of the monomorphic 
Eαk that pairs with the endogenous I-Eβb chain. B6 and B6.E+ mice had similar numbers of total 
thymocytes (1.79x108±2.45x107 cells vs 1.72x108 ± 1.65x107 cells, respectively). Broad analysis 
of thymocyte populations revealed similar percentages of B6 and B6.E+ CD4+ and CD8+ DN 
cells (10.1±1.3% vs. 8.7±0.4%, respectively), DP cells (65.9±3.1% vs. 65.9±2.7%, respectively), 
CD4+ SP cells (15.2±1.7% vs. 16.5±2.5%, respectively), and CD8+ SP cells (5.1±0.4 vs. 
5.3±0.3%, respectively) (Fig. 4.1A). However, more in-depth examination of the expression 
patterns of the TCR Vβ family members revealed differences. Certain Vβ family members, Vβ5, 
Vβ11, and Vβ12, were found to be decreased in both the B6.E+ CD4+ SP and CD8+ SP thymus 
populations (Fig. 4.1B). These results are in line with previous work attributing the I-E molecule 
to the thymic deletion of these exact Vβ family members, postulated to be mediated by 
superantigens (23, 36, 37). What was more interesting and novel is that B6.E+ CD4+ SP 
thymocytes had increased percentages of Vβ6 and Vβ10 compared to B6 (9.3±0.4% vs. 
6.6±0.3% for Vβ6 and 6.3±0.3% vs. 3.5±0.2% for Vβ10). These differences were not seen with 
CD8+ SP thymocytes, indicating they resulted directly from adding a class II MHC molecule 
(Fig. 4.1B). Additionally, analysis of DP thymocytes revealed none of the changes in Vβ 
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staining, suggesting that the altered repertoire in B6.E+ mice was due to selection-mediated 
effects (Fig. 4.1C). Further, splenic B6.E+ CD4+ T cells showed increases in the Vβ6 and Vβ10 
TCR-expressing populations compared to B6 (11.4±0.5% vs. 8.8±0.4% for Vβ6 and 7.3±0.1% 
vs. 4.1±0.2% for Vβ10) (Fig. 4.1D). This demonstrates that an altered TCR repertoire is 
maintained in the periphery and present to potentially change the pathogenesis of immune 
diseases. We predict that I-Eb expression would have a negative impact. 
 
Against allogeneic stimuli, expression of a second MHC molecule decreases the CD4+ T cell 
response 
 
To determine what impact MHC composition has on alloreactivity, a mixed lymphocyte reaction 
(MLR) was performed. 1.5 x 106 B6 and B6.E+ splenic CD4+ T cells were cultured with equal 
numbers of irradiated Balb/c (H-2d) or SJL (H-2s) APCs for 48 h, and IFNγ enzyme-linked 
immunospot (ELISPOT) was carried out to determine the frequency of alloreactive T cells. The 
B6.E+ alloreactive T cell frequencies were significantly decreased upon stimulation with both 
Balb/c and SJL APCs compared to B6 (232.6±72.8 vs. 518±87.8 for Balb/c and 97.9±16 vs. 
176.1±30.5 IFNγ spots/well for SJL). B6 and B6.E+ samples had similar responses to the 
nonspecific stimulation PMA + ionomycin (122.8±29.1 vs. 76.3±17.1 IFNγ spots/well, 
respectively) as well as to no stimulation (20±4.5 vs. 21±4.4 IFNγ spots/well, respectively) (Fig. 
4.2).  
 
Expression of I-Eb does not change the T cell response to HEL protein immunization 
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We were interesting in analyzing the B6.E+ T cell response in other types of immune models to 
determine if similar dampened T cell reactivity as in allorecognition would be seen or if the 
addition of I-Eb elicits different effects. Analysis of the T cell response to a single protein 
immunization was performed. We reasoned that should any changes be detected, this model 
would allow us to feasibly identify the individual epitope(s) responsible for the phenotype. The 
HEL protein was chosen because B6 mice exhibit minimal reactivity to it. Out of 11 HEL 
peptides spanning the entire 129 amino acid sequence of the protein, CD4+ and CD8+ T cells 
from B6 mice responded to only 3 epitopes (38, 39). We thought any alterations to the T cell 
response would be most discernible in a system where the antigen reactivity is moderate to begin 
with. B6 and B6.E+ mice were immunized in the hind footpads with HEL emulsified in CFA, 
and 7 days later draining lymph node cells were taken and stimulated in vitro with HEL for 4 
days. Samples were pulsed with [3H]TdR during the last 24 h and assessed for proliferation. We 
found that B6 and B6.E+ responses to multiple concentrations of HEL were similar, 
demonstrating that the addition of a second MHC molecule does not affect overall immune 
reactivity in this situation (Fig. 4.3A). Furthermore, B6 and B6.E+ T cell responses to purified 
protein derivative (PPD), containing Mycobacterium tuberculosis present in CFA, was 
compared. The similar proliferative responses to a more complex mixture of antigens 
underscored the lack of I-Eb-mediated differences in protein immunization (Fig. 4.3B). 
 
Addition of I-Eb impacts the quality of the CD4+ T cell response to LCMV  
 
We next investigated the CD4+ T cell response to viral infection to see the addition of a second 
MHC II molecule elicits differences in a disease model. B6 and B6.E+ mice were infected i.p. 
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with LCMV Armstrong, and 8 days later spleen cells were analyzed for frequency of LCMV-
specific T cells by tetramer stain. To narrow our focus, we chose to compare the B6 and B6.E+ T 
cell population specific to a defined I-Ab-restricted LCMV epitope, GP66-77, dominant in the 
CD4+ T cell response (40). Upon staining with the LCMV GP66-77/I-Ab tetramer, we found that 
B6.E+ mice exhibited similar frequencies of LCMV-specific T cells compared to B6 
(900.5±177.7 vs. 624.2±78.3 cells/105 CD4+ T cells, respectively) (Fig. 4.4A). T cell cytokine 
production was also assessed. To do this, splenic cells 8 d post-infection were stimulated ex vivo 
for 24 h with the I-Ab-restricted LCMV61-80 peptide containing no predicted I-Eb epitopes 
according to an I-Eb binding motif previously used for I-Eb peptide identification (41, 42) and 
then analyzed by flow cytometry. The production of individual cytokines such as TNFα by itself 
was comparable between B6 and B6.E+ CD4+ T cells (4.4±0.7% vs. 3.8±0.5%, respectively). But 
interestingly, the percentage of CD4+ T cells co-producing IFNγ and TNFα was reduced in B6.E+ 
mice compared to B6 (0.66±0.06% vs. 0.88±0.09%, respectively) (Fig. 4.4B).  
 
We wondered if the difference in B6.E+ CD4+ T cell production of IFNγ and TNFα was present 
only in an acute infection or if the cytokine decrease would persist throughout a chronic 
infection. Therefore, we performed chronic infection with LCMV CL13 by i.v. injection of 
2x106 pfu of virus. Our results corroborated the dampened T cell cytokine production seen in the 
B6.E+ mice compared to B6 (0.16±0.02% vs. 0.24±0.02%, respectively) at 28 d post-infection 
(Fig. 4.4C), demonstrating that the difference is not limited to acute LCMV infection. 
Altogether, expression of an additional MHC molecule resulted in a subtle impact on T cell 
immunity by keeping the frequency of antigen-specific CD4+ T cells the same but altering the 
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quality of the cytokine-producing T cell repertoire, diminishing the percentage of T cells 
producing multiple cytokines.  
 
I-Eb speeds the onset and increases the severity of EAE due to altered selection of the 
natural Treg (nTreg) population  
 
We were interested in examining B6.E+ mice in autoimmunity because there are opposing 
conclusions about what impact adding I-E has on autoimmune diseases. Though the majority of 
reports have demonstrated a protective role for I-E in a number of autoimmune models, a 
thorough study on autoimmune thyroiditis showed increased susceptibility imparted by I-E 
expression (22, 24-29). Our study provides a unique opportunity to relate the impact of I-E on 
autoimmunity to its effects on other types of immune responses, a comparison that has not been 
done before. Here, I-Eb has produced different effects on distinct immune models: it does not 
change the response to HEL protein immunization but alters the quality of the anti-viral response 
and diminishes alloreactivity. We wondered what result we would see in autoimmunity and 
whether it would be completely different or similar to any of our other models. We chose to 
investigate EAE because the impact of I-E on this autoimmune model has not been examined 
before and could provide further support for either a protective or detrimental role for I-E. B6 
and B6.E+ mice were immunized with MOG35-55 peptide emulsified in CFA and injected with 
pertussis toxin. Using similar reasoning as in our LCMV infection study, we chose to immunize 
with an I-Ab-restricted MOG peptide rather than whole protein so that we could perform a direct 
and focused comparison between the B6 and B6.E+ T cell response to a defined antigen.  
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After immunization, clinical scores were recorded throughout the course of disease. 
Unexpectedly, results revealed that B6.E+ mice had enhanced disease compared to B6, exhibited 
by earlier days of onset (11.2±0.43 vs. 14±0.9, respectively) as well as higher peak clinical 
scores (3.5±0.25 vs. 2±0.24, respectively) (Fig. 4.5 and Table 4.1). A possible explanation for 
increased autoimmunity would be an increased pathogenic T cell number or response. We 
therefore assessed T cell binding to MOG38-49/I-Ab tetramer and cytokine production. Due to the 
difference in day of onset, we chose a time-point early in disease when we reasoned differences 
in lymphoid organs would be most evident. At 13 d post-EAE induction, the frequencies of 
MOG/I-Ab-specific CD4+ T cells extracted from spleen and draining lymph nodes were similar 
between B6 and B6.E+ mice (221.3±41.1 vs. 203.4±24.3 cells/105 CD4+ T cells, respectively)  
(Fig. 4.6A). To look at cytokine production, spleen and draining lymph node cells were 
stimulated ex vivo with MOG35-55, and staining for cytokines relevant to EAE pathogenesis – 
IFNγ, IL-17, and TNFα – was performed and assessed by flow cytometry (43, 44). Surprisingly, 
B6 and B6.E+ CD4+ T cells had similar production of all three cytokines (1.2±0.3% vs. 
0.9±0.1%, respectively, for IFNγ; 0.18±0.03% vs. 0.14±0.02% for IL-17; and 1.2±0.2% vs. 
1.1±0.1% for TNFα) (Fig. 4.6B).  
 
An alternative explanation for enhanced EAE disease is that it resulted not from increased T cell 
pathogenicity, but from decreased Treg cells. To test this, the percentage of Foxp3+ CD4+ Treg 
cells was assessed 13 days after EAE induction. Interestingly, a significantly decreased 
percentage of Treg cells was seen in B6.E+ mice compared to B6 (8.7±0.8% vs. 12.7±1.2%, 
respectively) (Fig. 4.7A). To determine whether nTreg cells – which are generated in the thymus 
– are the subset affected, we stained the cells for Helios, a marker of nTreg cells (45). A 
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significant reduction in the percentage of nTreg cells during EAE was observed in B6.E+ mice 
compared to B6 (63.9±2.2% vs. 72.4±2.5%, respectively), implicating a thymic selection-
mediated effect of I-Eb on the Treg cell population (Fig. 4.7B). Analysis of Foxp3 staining in 
spleen and lymph node cells from naive mice revealed that the decrease in Treg cells was not 
present in B6.E+ mice prior to disease (9±0.6% B6 vs. 8.1±0.9% B6.E+) (Fig. 4.7C). It appears 
that perturbation of the immune system through autoimmunity was necessary to expose the 
defect of the B6.E+ Treg cell repertoire. Put together, these EAE results provide interesting and 
novel insight into the differential susceptibility of self-reactive, Treg cells to increased negative 
selection imparted by the expression of a second class II MHC molecule in autoimmunity. 
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Discussion 
 
Throughout the years, immunologists have been intrigued by the biological implications for the 
limit on the number of MHC molecules expressed in an individual. Knowing that the role of the 
MHC is to present peptides to T cells, it is reasonable to think that having additional MHC 
molecules would result in significantly beneficial consequences; expansion of the T cell 
repertoire during positive selection as well as an increase in the presented peptide repertoire in 
the periphery should both enhance T cell responses to pathogens. However, MHC molecules also 
participate in negative selection, and it is possible this would balance out or even overcome the 
effects from positive selection. We compared B6 mice, which have only one class II MHC 
molecule, I-Ab, to B6.E+ mice, which have both I-Ab and I-Eb, in order to see what would result 
from expressing a second class II MHC molecule. Specifically, we were interested in 
determining the effect on CD4+ T cell alloreactivity and if the differences seen, if any, would be 
observed across a wide variety of T cell responses. 
 
Examination of naive B6 and B6.E+ mice revealed distinct TCR usage. B6.E+ mice exhibited 
higher percentages of CD4+ T cells expressing Vβ6 and Vβ10 as well as decreased percentages 
of Vβ5, Vβ11, and Vβ12 CD4+ and CD8+ T cells. Though the changes in Vβ5, Vβ11, and Vβ12 
expression have been shown before to be mediated by I-E and superantigen (23, 36, 37), the 
finding that there is increased Vβ6- and Vβ10-expressing CD4+ T cells upon addition of I-Eb is 
novel. We discovered that the addition of a second MHC molecule resulted in diverse effects, 
including significantly decreased alloreactivity, no net difference in the T cell response to HEL 
protein immunization, a subtle alteration to the LCMV-reactive T cell repertoire, and enhanced 
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autoimmunity accompanied by diminished nTreg percentages. Based on a reported I-Eb binding 
motif (41, 42), there is one putative I-Eb peptide epitope in HEL. It is possible that though both I-
Ab and I-Eb contribute to the response to HEL in the B6.E+ mice, there was no net change in 
reactivity due to the altered HEL-specific I-Ab and I-Eb T cell repertoires balancing out. Or, 
another explanation is that there is no I-Eb-restricted response to HEL in the B6.E+ mice. We saw 
that having additional antigens present and more complex immune disease models resulted in 
changes to the T cell response. Most intriguingly, the significantly enhanced autoimmunity in 
B6.E+ mice (Fig. 4.5) supports our hypothesis that negative consequences on immunity limit the 
number of MHC molecules expressed. 
 
We think our results can be reasonably explained by enhanced MHC-mediated negative selection 
dominating the effects from any increase in positive selection. For alloreactivity, thymic 
selection is known to play a significant role in shaping the alloreactive T cell repertoire. Positive 
selection results in T cells that can bind to many different allogeneic MHC molecules, while 
negative selection establishes MHC restriction and peptide specificity (46). We show here that 
the effects of negative selection outweigh those of positive selection, resulting in decreased 
alloreactive T cells in B6.E+ mice. This decrease may have both beneficial and detrimental 
clinical consequences, theoretically leading to less GVHD or transplant rejection but diminishing 
the graft-versus-leukemia effect that eliminates tumors (47). Since H-2d APCs express both I-A 
and I-E while the H-2s APCs have only I-A, we can compare the I-E- and I-A-specific 
alloresponse to the I-A-only alloresponse. Not unexpectedly, there was a greater magnitude of 
alloreactivity to the H-2d APCs compared to H-2s, demonstrating the contribution of two 
allogeneic MHC molecules rather than one for stimulation. Compared to B6, B6.E+ CD4+ T cells 
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exhibited an approximately 50% decrease in alloresponse to both H-2d and H-2s APCs. This 
indicates that I-Eb in B6.E+ mice can alter the T cell repertoire to affect the alloresponse to a 
single allogeneic MHC, I-As, and that having two allogeneic MHC molecules, I-Ad plus I-Ed, 
does not provide enough alloligands to enhance the level of B6.E+ alloreactivity to equal B6. 
Whether there are similar reductions in the number of B6.E+ T cells specific to individual 
allopeptides could be established in the future using H-2d or H-2s pMHC tetramers. 
 
For the LCMV data, the decreased percentage of B6.E+ CD4+ T cells producing IFNγ and TNFα 
in response to LCMV stimulation suggests that I-Eb increases the deletion of polyfunctional 
LCMV-specific T cells. Sequence analysis of naturally occurring peptides eluted from I-Ab and 
I-Eb revealed distinct sequence motifs between the two MHC molecules (48). This lends support 
for the idea of I-Eb introducing a different set of pMHC ligands during thymic selection and 
altering the resulting T cell repertoire. Polyfunctional T cells that produce multiple cytokines 
have been associated with better protection from parasitic infection and more effective control of 
viral infection (49, 50). Thus, though the difference is subtle, it is possible that the altered T cell 
repertoire in B6.E+ mice can impact viral load or disease course in subsequent challenges. 
 
For EAE, unlike the two previous models, we did not detect a change in the B6.E+ effector T cell 
population that would explain the enhanced autoimmunity. In this case, the Treg population was 
diminished. Further investigation identified nTreg cells as being affected, lending support for I-
Eb impacting thymic development. It is possible that adding I-Eb during selection increases the 
chance that high affinity T cells differentiating into the Treg lineage – often characterized as 
experiencing a near-death encounter – are pushed into being negatively selected (51). The fact 
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that MOG is expressed in medullary thymic epithelial cells (52) supports this idea. Taking into 
account work demonstrating a saturable Treg cell selecting niche, in which the number of Tregs 
in the ensuing T cell repertoire plateaus when clonal frequency is increased (53), it may be that 
Tregs selected on I-Eb compete with and limit Tregs selected on I-Ab. This would lead to a 
decreased ability for the I-Ab-selected Tregs to expand and function in a MOG35-55/I-Ab-induced 
EAE model. It is interesting that effector T cells in EAE were not impacted considering the 
increased T cell cytokine production seen upon depletion of Treg cells in multiple peptide 
immunization-induced EAE models (54, 55). This likely reflects a difference in degree of 
immune suppression when Tregs are depleted in other models vs. decreased in our case. 
Moreover, epitope spreading is known to play a role in EAE, in which T cell reactivity extends 
to antigens other than what was used to induce disease, which can become accessible through 
processes such as tissue destruction (56). Perhaps in B6.E+ mice, effector T cells specific to I-Ab- 
or I-Eb-bound self peptides other than MOG35-55 are impacted, which we did not test in our study.  
 
Another issue relevant to all of our immune models is the possibility that Eα52-68, a peptide 
derived from the Eα gene product, binds to I-Ab and plays a role in dampening immunity. As the 
peptide is capable of occupying approximately 10-15% of all I-Ab molecules (29, 57), it can 
prevent the selection of certain I-Ab-restricted cells in the thymus or compete with the 
presentation of pathogenic peptides in the periphery. The Eα peptide along with the I-Eb MHC 
could both contribute to the altered T cell repertoire and T cell responses in the B6.E+ mice. 
Intrathymic injection of the peptide into B6 mice and addition of the peptide to in vitro 
stimulations for competition with LCMV or MOG would aid in understanding what extent Eα52-
68 /I-Ab plays in B6.E+ T cell selection and peripheral responses, respectively. 
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In contemplating the evolution of the immune system, though adaptive immunity has given 
vertebrates advantages such as memory, it has also led to significant drawbacks of 
immunopathology, hypersensitivity, and autoimmunity that result from heightened responses 
(58). Similar to this phenomenon, our work indicates that a more complex immune system with 
the addition of a second class II MHC molecule elicits enhanced autoimmunity, a decidedly 
negative consequence. Though the results from the other immune models elicited more benign 
effects – no difference in HEL protein immunization, subtle alteration of the LCMV response, 
and decreased alloreactivity that may be both positive and negative – the detrimental impact on 
autoimmunity stands out as a clear deterrent to the expression of more MHC molecules. 
Interestingly, chickens have a minimal essential set of MHC genes within a region approximately 
20-fold smaller than the human MHC locus, yet this simple and compact MHC still allows for 
sufficient immune responses (59). Humans, on the other hand, express a more diverse set of 
MHC molecules than our laboratory mouse strains. Conclusions from our work would imply that 
the more complex human MHC may lead to less ideal immune responses. It is in fact true that 
humans experience autoimmune diseases, many of which are highly associated with the MHC. 
This is consistent with our result of enhanced autoimmunity when adding an extra MHC 
molecule to the system. Perhaps humans require a certain high number of MHC molecules in 
order to combat the diverse repertoire of pathogens we have faced whereas the complexity of 
pathogens other vertebrates encounter could be sufficiently resisted with lower numbers of 
MHC. Knowing how different the environment is for each species, our model of expressing one 
additional MHC molecule, I-E, in mice is essential to experimentally address and then better 
understand what impact MHC number has on immune responses.
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Figure 4.1 The expression of a second class II MHC molecule, I-Eb, alters the naive thymic 
and peripheral T cell repertoire as a result of thymic selection-mediated effects 
(A) B6 and B6.E+ thymocytes were analyzed by flow cytometry for total number of thymocytes 
as well as percentage of CD4+ and CD8+ DN, DP, and SP cells. Each point represents a single 
mouse, n = 7-8 from 3 independent experiments, mean ± sem. Mann-Whitney statistical test was 
performed. (B) The TCR repertoire of B6 and B6.E+ thymic CD4+ and CD8+ T cells was 
examined by staining for a panel of TCR Vβ family members, n = 8 mice from 3 independent 
experiments, mean ± sem. 2-way ANOVA test was conducted. (C) The percentage of CD4+ 
CD8+ DP thymocytes positive for each Vβ is depicted for B6 and B6.E+ samples, n = 8 mice 
from 3 independent experiments, mean ± sem, 2-way ANOVA test. (D) TCR Vβ staining was 
also performed on splenic CD4+ T cells, n = 5 mice from 2 independent experiments. Data are 
shown as mean ± sem, with 2-way ANOVA test.
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Figure 4.1 The expression of a second class II MHC molecule, I-Eb, alters the naive thymic 
and peripheral T cell repertoire as a result of thymic selection-mediated effects  
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Figure 4.2 Against allogeneic stimuli, expression of I-Eb decreases the CD4+ T cell response 
1.5 x 106 B6 and B6.E+ splenic CD4+ T cells were cultured at a 1:1 ratio with Balb/c (H-2d) and 
SJL (H-2s) APCs. Stimulation with PMA (20ng/mL) + ionomycin (1µM) and medium were used 
as positive and negative controls, respectively. Data are shown as mean ± sem, n = 6-9 samples 
compiled from 2-3 independent experiments, unpaired t test. 
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Figure 4.3 Expression of I-Eb does not change the T cell response to HEL protein 
immunization  
T cells from B6 and B6.E+ mice immunized with 20 nmol HEL protein emulsified in CFA were 
stimulated in culture for 4 d with varying concentrations of (A) HEL and (B) a dilution series of 
PPD. [3H]TdR was added during the final 24 h of culture, and proliferation was measured. No 
stimulation (0µM) data points are depicted to show background CPM. Data are shown as mean ± 
SD and are representative of three experiments.
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Figure 4.4 Addition of I-Eb impacts the quality of the CD4+ T cell response in LCMV 
infection  
(A, B) Mice were infected i.p. with 4 x 105 pfu LCMV Armstrong, and 8 d post-infection splenic 
T cells were analyzed. (A) Cells were stained with LCMV/I-Ab APC-labeled tetramer, enriched 
by magnetic selection using anti-APC beads, stained for surface markers, and assessed by flow 
cytometry. Representative plots of CD4+ and CD8+ T cell tetramer-positive populations from B6 
and B6.E+ mice are shown (left) as well as combined data of the number of tetramer-positive 
CD4+ T cells with each point depicting one mouse from two independent experiments, mean ± 
sem, Mann-Whitney test (right). (B) Cells were also stimulated ex vivo with 10µg/mL LCMV 
GP61-80 peptide for 24 h followed by intracellular cytokine staining for TNFα and IFNγ. 
Representative plots are shown depicting cytokine-positive populations from B6 and B6.E+ 
CD4+ T cells (left) along with combined data for TNFα positive CD4+ T cells and TNFα and 
IFNγ double positive CD4+ T cells, each point representing one mouse from two independent 
experiments, mean ± sem, Mann-Whitney test (right). (C) Mice were chronically infected i.v. 
with 2 x 106 pfu of LCMV CL13. At 28 d post-infection, spleen cells were stimulated ex vivo 
with 10µg/mL LCMV GP61-80 for 24 h, and cytokine production was assessed by flow cytometry. 
Representative B6 and B6.E+ plots of TNFα and IFNγ positive populations are shown (left) 
along with combined data, each point representing one mouse from two independent 
experiments, mean ± sem, Mann-Whitney test (right).
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Figure 4.5 I-Eb speeds the onset and increases the severity of EAE  
EAE was induced with sub-cutaneous (s.c.) immunization of MOG35-55 peptide emulsified in 
CFA plus i.p. injection of pertussis toxin and scored up to 28 d post-immunization on a five point 
scale: 0 = no weakness, 1 = limp tail, 2 = mild hindlimb paresis, 3 = moderate to severe hindlimb 
paresis, 4 = complete hindlimb paresis, 5 = moribund or dead. Results are mean ± sem at each 
timepoint and representative of three independent experiments. 
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Figure 4.6 Enhanced EAE in mice expressing I-Eb is not associated with increased 
pathogenic T cell number or response  
EAE was induced with s.c. immunization of MOG35-55 peptide emulsified in CFA plus i.p. 
injection of pertussis toxin. At 13 d post-immunization, spleen and draining lymph node cells 
were taken for analysis. (A) Cells were incubated with MOG/I-Ab or human clip/I-Ab (negative 
control) PE-labeled tetramer, enriched with anti-PE magnetic beads, and stained with surface 
markers for flow cytometry. Representative plots of B6 and B6.E+ CD4+ T cell tetramer positive 
populations are shown (left) as well as combined data depicting the number of MOG/I-Ab 
tetramer positive CD4+ T cells with each point representing one mouse from four independent 
experiments, mean ± sem, Mann-Whitney test (right). (B) Cells were stimulated with 10-
20µg/mL MOG35-55 for 24 h, stained for intracellular cytokines, and analyzed by flow cytometry. 
Representative plots of cytokine positive CD4+ T cells are shown (left) as well as combined data 
from 10 mice over three independent experiments, mean ± sem, Mann-Whitney test (right).
	   126	  
Figure 4.6 Enhanced EAE in mice expressing I-Eb is not associated with increased 
pathogenic T cell number or response  
Te
tra
m
er
+/
10
5  
C
D
4+
 T
 c
el
ls
B6 B6.E+
0
200
400
600
%
 c
yt
ok
in
e 
po
si
tiv
e 
C
D
4+
 T
 c
el
ls
IFNȖ IL-17 TNFĮ
0.0
0.5
1.0
1.5 B6
B6.E+
A
B
Tetramer
CD44
B6 MOG/I-Ab
3.56
B6 clip/I-Ab
0.047
B6.E+ MOG/I-Ab
3.74
B6.E+ clip/I-Ab
0.026
TNFĮ
IFNȖ
IL-17
2.17 0.14
0.16
B6 B6B6.E+
1.22 0.059
0.16
0.21 0.1
1.91
B6.E+
0.06 0.01
1.12 	  
	   127	  
Figure 4.7 I-Eb-mediated enhanced EAE is associated with decreased nTreg cells  
EAE was induced with s.c. immunization of MOG35-55 peptide emulsified in CFA plus i.p. 
injection of pertussis toxin. (A, B) At 13 d post-immunization, spleen and draining lymph node 
cells were taken for analysis. (A) Cells were stained for intracellular Foxp3 expression. 
Representative flow cytometry plots of Foxp3 positive B6 and B6.E+ CD4+ T cell populations 
are shown (left) as well as combined data (right). (B) Intracellular Helios staining was also 
performed, representative plots of CD4+ T cells (left) and combined data (right) are depicted. (C) 
Intracellular staining of Foxp3 in naive splenocytes and lymph node cells was done, with 
representative plots (left) and combined data (right) of CD4+ T cells shown. The combined data 
are from three independent experiments with each point on the graphs representing one mouse 
and are shown as mean ± sem, Mann-Whitney test.
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Table 4.1 Compilation of EAE results from four independent experiments  
EAE was induced with s.c. immunization of MOG35-55 peptide emulsified in CFA plus i.p. 
injection of pertussis toxin and scored up to 28 d post-immunization on a five point scale: 0 = no 
weakness, 1 = limp tail, 2 = mild hindlimb paresis, 3 = moderate to severe hindlimb paresis, 4 = 
complete hindlimb paresis, 5 = moribund or dead. 
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Table 4.1 Compilation of EAE results from four independent experiments 
Mouse Genotype B6 B6.E+ P value (Mann-Whitney test) 
Incidence of disease 20/20 18/18  
Day of onset (mean ± sem) 14 ± 0.9 11.2 ± 0.43 0.015 
Peak clinical score (mean ± sem) 2 ± 0.24 3.5 ± 0.25 0.0001 
 	  
	   131	  
Methods 
 
Mice 
Balb/c, B6, and SJL mice were purchased from The Jackson Laboratory. B6.E+ mice were the 
kind gift of Chella David (Mayo Clinic), and were derived from insertion of the monomorphic 
Eαk transgene into C57BL/6 x SJL embryos (60), which pairs with the endogenous I-Eβb chain 
thus allowing the expression of I-Eb. The mice were extensively backcrossed with C57BL/6 mice 
onto the H-2b background, and this was confirmed by analysis of microsatellite markers at the 
Rheumatic Disease Core Center, Washington University School of Medicine (St. Louis, MO). 
Mice were bred and housed in specific pathogen-free conditions at the animal facility at the 
Washington University Medical Center (St. Louis, MO).  All use of laboratory animals was 
approved and performed in accordance with the Washington University Division of Comparative 
Medicine guidelines. 
 
Flow cytometry 
Analysis of thymocytes and peripheral T cell populations was performed using anti-CD3 (145-
2C11)-PE-Cy7, anti-CD25 (eBio3C7)-eFluor 450, anti-Foxp3 (FJK-16s)-PE (eBioscience), anti-
Helios (22F6)-Alexa Fluor 647, anti-CD44 (IM7)-Alexa Fluor 700, anti-CD4 (RM4-5)-PerCP, 
anti-CD8a (53-6.7)-APC-Cy7 (Biolegend), and anti-Vβ TCR-FITC screening panel (BD 
Biosciences). All samples were analyzed using LSR II or LSR Fortessa cytometers (BD 
Biosciences) with calculated compensation, and the data were analyzed with FlowJo software 
(Tree Star). 
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Proliferation assay 
Mice were immunized s.c. with 20 nmol HEL emulsified in CFA (Difco).  After 7 days, draining 
lymph nodes cells were harvested, and 0.5-1 x 106 cells were plated in triplicate with medium 
only, varying concentrations of HEL, or 50µg/mL PPD of Mycobacterium tuberculosis for 4 
days in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum (PAA), 
5x10-5 M 2-ME (Sigma-Aldrich), 2mM GlutaMAX (Life Technologies), 1mM sodium pyruvate 
(Cellgro), 0.1mM non-essential amino acids (Lonza), 25mM HEPES buffer (Cellgro), and 
50µg/mL gentamicin (Life Technologies), with 0.4µCi tritiated thymidine ([3H]TdR) added for 
the last 24 h of culture. Assays were harvested on a Skatron cell harvester and counted using a 
LKB (Pharmacia/LKB) β plate counter. 
 
MLR and ELISPOT 
B6 and B6.E+ splenic CD4+ T cells were obtained by incubating cells with anti-CD4 microbeads 
for 30 min. at 4°C and flowing samples through magnetized LS positive selection columns 
(Miltenyi Biotec). 1.5 x 106 T cells were cultured for 48 h with equal numbers of irradiated 
Balb/c or SJL splenocytes, 20ng/mL phorbol 12-myristate 13-acetate (PMA) + 1µg/mL 
ionomycin, or medium only in 96-well MultiScreen-IP plates (Millipore) coated with purified 
anti-IFNγ (RA-6A2; eBioscience). Plates were then incubated with biotinylated anti-IFNγ 
(XMG1.2; eBioscience) and streptavidin-conjugated HRP (Southern Biotech), developed with 5-
bromo-4-chloro-3-indoyl phosphate/nitro blue tetrazolium (BCIP/NBT; Sigma-Aldrich), read on 
a CTL ImmunoSpot reader, and analyzed using CTL ImmunoSpot 4.0 (Cellular Technology 
Limited). 
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LCMV infection 
Acute infection was performed by i.p. infection with 4 x 105 pfu LCMV Armstrong, and spleen 
cells were taken at 8 d post-infection for tetramer and intracellular cytokine stains. Chronic 
infection was done with i.v. infection of 2 x 106 pfu LCMV CL13, and at 28 d post-infection 
spleen cells were taken for intracellular cytokine analysis. 
 
Tetramer enrichment 
LCMV GP66-77 (DIYKGVYQFKSV) bound to I-Ab (LCMV/I-Ab)-APC and MOG38-49 
(GWYRSPFSRVVH) bound to I-Ab (MOG/I-Ab)-PE tetramer were used to analyze antigen-
specific T cells. Tetramers were obtained from the NIH Tetramer Core Facility at Emory 
University (Atlanta, GA). Enrichment was conducted according to published protocols (61). In 
brief, cells were stained with tetramer for 1 h at room temperature, washed, incubated with anti-
PE or anti-APC conjugated microbeads for 30 min. at 4°C, and passed over magnetized LS 
columns for positive selection (Miltenyi Biotec). The enriched cell populations were labeled with 
antibodies to cell surface markers for 20 min. at 4°C and analyzed by flow cytometry. 
 
Intracellular cytokine stain 
Cells were cultured with the indicated peptide – 10µg/mL for LCMV61-80 
(GLNGPDIYKGVYQFKSVEFD) and 10-20µg/mL for MOG35-55 – for 24 h with 10µg/mL 
Brefeldin A (Sigma-Aldrich) added during the last 4 h.  Live cells were stained using 
LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes), labeled with surface marker 
mAbs, fixed with 4% paraformaldehyde (Sigma-Aldrich), permeabilized with 0.5% saponin 
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buffer, and intracellularly stained with anti-IFNγ (XMG1.2)-FITC, IL-17 (TC11-18H10.1)-PE, 
and TNFα (MP6-XT22)-PE (Biolegend). 
 
EAE induction and scoring 
EAE was induced by s.c. immunization over four flanks with 200µL total volume of 200µg 
MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) emulsified in 500µg CFA (diluted from 
10mg/mL M. tuberculosis H37Ra, Difco, in Incomplete Freund’s Adjuvant, Sigma) and i.p. 
injection of 200ng pertussis toxin (List Biological Laboratories, Inc.). Spleen and draining lymph 
node cells at 13 d post-immunization were taken and stained for flow cytometry analysis. Mice 
were clinically scored on a five point scale for signs of disease.  0 = no weakness, 1 = limp tail, 2 
= mild hindlimb paresis, 3 = moderate to severe hindlimb paresis, 4 = complete hindlimb paresis, 
5 = moribund or dead.
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Much insight has been gained in understanding the contributing factors to T cell alloreactivity by 
our lab and others. This includes the remarkable discovery of germline-encoded contacts 
between TCR and MHC (1-3); findings that suggest an importance for the allopeptide in 
alloreactivity (4-6); as well as an appreciation for the contribution of secondary TCRs, which do 
not mediate positive selection but arise from simultaneous and continuous TCRα chain 
rearrangement during the selection process (7). However, there are still questions about how 
CD4+ T cells recognize allostimulatory pMHC ligands that remain unanswered and are integral 
for gaining a full picture of how alloreactivity occurs. There are two main questions: 1. How 
does CD4+ T cell alloreactivity compare to recognition of cognate ligands? and 2. How do 
factors involved in thymic selection, namely secondary TCRs and the composition of the MHC, 
impact the alloreactive T cell population that ensues?  
 
CD4+ T cells recognize allogeneic pMHC ligands with the same properties used in 
conventional recognition 
 
A comparison of CD4+ T cell alloreactivity and conventional recognition is key to understanding 
alloreactivity because it has not been performed before, and results from CD8+ T cells 
conflictingly suggest that alloreactivity can be different from and highly similar to binding 
cognate ligands (8, 9). To address this issue, allostimulatory peptides were identified for two 
CD4+ T cells, LLO118 and 1G5.1, both responsive to LLO/I-Ab as their cognate ligand. 
LLO118, naturally alloreactive to I-Ek APCs, was found to alloreact to a kidins220 peptide 
presented by I-Ek. Though not naturally alloreactive to I-Ek, 1G5.1 was shown to respond to an 
allopeptide mimic, Hb F70. A direct comparison of LLO118 and 1G5.1 alloreactive and 
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conventional recognition revealed a high degree of peptide specificity in both types of responses. 
Additionally, biochemical studies of LLO118 suggested very similar binding kinetics and 
affinity values between alloreactivity and cognate recognition. Thus, these studies of CD4+ T 
cells favor the interpretation that alloreactivity exhibits highly similar binding properties 
compared to cognate pMHC recognition. 
 
The ultimate goal in understanding how the TCR binds pMHC is to generate a crystal structure 
of the TCR co-complexed with its ligand. For future investigations, it would be informative to 
have crystal structures for LLO118 and 1G5.1 bound to both cognate and allostimulatory pMHC 
to structurally compare conventional vs. alloreactive recognition as well as compare how two T 
cells bind the same cognate pMHC, LLO/I-Ab. From the solved crystal structures of TCRs 
complexed to their alloligands available in the field, it is interesting that binding to the 
allopeptide plays an integral role in allorecognition. For instance, upon binding allogeneic MHC 
molecules presenting the same peptide seen in cognate recognition, the TCR (examples from 
both class I and class II MHC-restricted T cells) focused on recognizing peptide conformational 
changes induced by the allogeneic MHC (10, 11). That TCR CDR3 loop flexibility explained the 
ability of a TCR to bind two different H-2Kb alloligands further supports the importance of 
allopeptide recognition (12). Knowing this, we predict that in binding their alloligands, LLO118 
and 1G5.1 will retain canonical TCR binding properties - including the diagonal orientation of 
the TCR over the pMHC surface - but the TCRs will use different contact sites and types of 
bonds given how different the allostimulatory and cognate peptides are. We think the binding 
would be like how the 2C TCR binds its allostimulatory and cognate ligands, with divergent 
mechanisms and dissimilar interactions between its paired peptides (8). Additionally, it will be 
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interesting to see what insight the comparison of LLO118 and 1G5.1 binding to LLO/I-Ab would 
give us. Other structural studies assessing multiple T cells binding the same ligand showed 
superimposable interactions and pinpointed amino acids that mediate germline affinity (13, 14). 
The T cells used in the studies were more similar to each other than LLO118 and 1G5.1 are (all 
were of the TCR Vβ8 family), but we think it may be possible certain peptide or MHC residues 
may be similarly bound by two distinct TCRs. Furthermore, how any similarities impact 
LLO118 and 1G5.1 allorecognition would be very fascinating to analyze. 
 
Rearrangement of dual TCRs enhances positive selection and leads to increased 
alloreactive and autoreactive T cell repertoires 
 
Understanding how thymic selection impacts alloreactivity is critical for gaining insight into the 
formation of alloreactive T cells. Previous work on dual TCR T cells in humans revealed their 
increased numbers and activation in patients with acute GVHD (15). In mice, the genetic 
elimination of dual TCR T cells resulted in a nearly 50% decrease in T cell alloresponse to bulk 
APCs in vitro despite the fact that only 10% of peripheral T cells express dual TCRs, 
demonstrating a disproportionate contribution of dual TCR T cells to alloreactivity (7). We 
sought to extend the studies on TCRα+/- mice, which only rearrange one TCRα locus and thus 
cannot develop dual TCRs, to examine the role of simultaneous TCRα rearrangement on T cell 
development as well as the contribution of dual TCR T cells to recognition of individual 
allopeptides and in vivo alloreactivity. We reasoned that simultaneous TCRα rearrangement 
enhances T cell selection but results in dual TCR T cells that participate in atypical immune 
responses. We hypothesized that the secondary TCR resulting from simultaneous TCRα 
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rearrangement exhibits altered binding properties that allow dual TCR T cells to contribute so 
significantly to alloreactivity.  
 
Our results showed deficient generation of SP thymocytes attributable to a decrease in the 
efficiency of positive selection in TCRα+/- mice. Additionally, our work further established the 
contribution of dual TCR T cells to alloreactivity, revealing significantly decreased binding to 
allo- and auto-pMHC tetramers as well as alloreactivity in vivo of TCRα+/- T cells. Interestingly, 
TCR sequence analysis revealed a non-random elimination of certain TCRs from the repertoire 
when secondary TCRα rearrangement was disabled. We found that dual TCR T cells exhibited a 
great deal of flexibility in allopeptide recognition and could respond to multiple peptide APLs, 
suggesting that secondary TCRα rearrangement enables TCRs with altered binding properties to 
make it past thymic selection and contribute disproportionately to alloreactivity. What is 
fascinating is that altered binding of T cells has been noted for another atypical immune 
response, autoimmunity. The crystal structure of a human TCR involved in multiple sclerosis 
complexed with self pMHC revealed an unconventional binding mode, with the TCR footprint 
shifted from a canonical, central orientation to the N-terminus of the peptide and the CDR3 loops 
dominating binding to the pMHC (16). The crystal structure of another autoreactive TCR 
involved in diabetes complexed with its auto-pMHC showed abnormal, highly peptide-centric 
interactions, with at least 69% of TCR-pMHC contacts made with the peptide (17). It is 
speculated that altered binding properties allow the autoreactive TCR to escape thymic negative 
selection. Likewise, it seems reasonable that dual TCR T cells also exhibit altered binding in 
alloreactivity since they can contain a TCR that also evades thymic selection pressures, as it does 
not need to mediate positive selection and can mask another TCR from negative selection. That 
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altered binding seems to predominantly involve the peptide is not surprising. With germline 
affinity governing CDR1 and CDR2 interactions with the MHC, the T cell is left with CDR3 
loops to exhibit more flexibility in binding the peptide or entire pMHC surface.  
 
It would be interesting to further investigate dual TCR T cells in autoimmunity. Our results 
showed decreased TCRα+/- T cell binding to the EAE autoantigen, MOG/I-Ab. Though previous 
work did not see any differences in disease after EAE induction, that study used a 
proteolipoprotein peptide to immunize the TCRα+/- mice on a different background (SJL) 
compared to ours (B6). It is possible that TCRα+/- mice on the B6 background immunized with 
the MOG peptide epitope bound by a decreased frequency of TCRα+/- T cells would elicit 
differences in EAE disease. Additionally the course of disease in SJL mice versus B6 mice is 
different, with the former exhibiting relapsing-remitting disease and the latter showing chronic 
symptoms without remission (18-20). This distinction could lead to different results when using 
TCRα+/- mice on the SJL and B6 backgrounds. 
 
Expression of an additional class II MHC molecule elicits diverse effects on different 
immune responses 
 
There is evidence that MHC molecules present during selection can shape the alloreactive T cell 
repertoire, with positive selection resulting in a highly alloreactive T cell population that 
becomes restricted by negative selection (21), the selecting MHC affecting the avidity of T cells 
for alloantigen (22), and homology of the self and allogeneic MHC impacting allopeptide 
recognition (23). It is unknown what impact on T cell alloreactivity ensues from increasing the 
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types of MHC expressed. Studies have looked at the effect of MHC number on the T cell 
response to pathogens and in autoimmunity, using mice expressing an additional MHC class II 
molecule (ie. comparing mice with both I-E and I-A vs. mice with just I-A) as well as comparing 
MHC heterozygote mice versus MHC homozygote mice. Results from these studies have shown 
that a more complex MHC repertoire can be beneficial and detrimental in pathogen resistance 
and protection from autoimmunity, depending on the pathogen and autoimmune model (24-36).  
 
We were interested in investigating the impact on alloreactivity from increasing the number of 
MHC molecules expressed. We wondered whether adding more MHC would increase positive 
selection and alloreactivity, or whether it would enhance negative selection and negate the 
effects of positive selection. To address this, we examined B6.E+ mice, which have an Eαk 
transgene and thus express an additional class II MHC (I-Eb, I-Ab) compared to B6 mice (I-Ab 
only). B6.E+ CD4+ T cell response to H-2d and H-2s APCs in MLR experiments showed a 
significantly decreased alloresponse compared to B6. In addition to an impact on alloreactivity, 
the addition of I-Eb also affected other types of immune responses, altering the cytokine 
production in LCMV infection and enhancing EAE possibly through decreasing Treg cells. We 
think our results are consistent with enhanced negative selection from adding I-Eb that dominates 
any effects from increased positive selection, thus resulting in decreased alloreactivity and Treg 
cells as well as an altered LCMV-specific T cell repertoire. Our work is novel because previous 
studies did not examine whether adding a particular MHC elicits distinct effects on different T 
cell responses, only investigating the impact on one disease model. We now know that diverse 
effects result from adding I-Eb, including a hitherto unappreciated impact on alloreactivity. 
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In the future, it would be insightful to understand the extent of decreased alloreactivity of B6.E+ 
T cells. Currently, we know that I-Eb expression diminishes the naive alloreactive T cell 
frequency to H-2d and H-2s APCs. Does I-Eb affect the T cell response to individual peptides? 
pMHC tetramers with I-Ad, I-Ed, or I-As MHC could be used to address this. Additionally, 
whether B6.E+ T cells elicit diminished alloreactivity in vivo would be interesting to determine. 
GVHD or solid organ transplant models could be performed to assess this, potentially yielding 
clinically relevant insight into the extent T cells selected in an environment with one additional 
MHC molecule can mediate GVHD or rejection. Finally, though we believe our results of 
decreased alloreactivity as well as Tregs in autoimmunity support a negative selection effect 
from I-Eb, it is possible that positive selection is at play. To investigate this, and rule out positive 
selection-mediated impacts, bone marrow chimera experiments could be performed in the future. 
Different combinations of B6 and B6.E+ bone marrow and irradiated recipient mice would be set 
up and used for MLR experiments to determine if I-Eb expression on radio-sensitive bone 
marrow cells (that participate in negative selection) or radio-resistant thymic stromal cells 
(involved in positive selection) is required to select out T cells with decreased alloreactivity. 
 
To conclude, our work has shown that CD4+ T cells recognize their allostimulatory pMHC 
ligands with a high degree of allopeptide specificity, weak affinity similar to conventional 
recognition, increased flexibility of binding upon expression of dual TCRs, and diminished 
reactivity when T cells come from an environment with additional MHC expressed. Moving 
forward, the field of T cell alloreactivity would benefit from structural comparisons of CD4+ T 
cell alloreactivity with conventional recognition as well as more work on allopeptide recognition 
and in vivo alloreactivity of T cells coming from mice expressing increased types of MHC 
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molecules.
	   148	  
References 
1. Marrack, P., J. P. Scott-Browne, S. Dai, L. Gapin, and J. W. Kappler. 2008. 
Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu. Rev. 
Immunol. 26: 171-203. 
2. Scott-Browne, J. P., J. White, J. W. Kappler, L. Gapin, and P. Marrack. 2009. Germline-
encoded amino acids in the alphabeta T-cell receptor control thymic selection. Nature 
458: 1043-1046. 
3. Rubtsova, K., J. P. Scott-Browne, F. Crawford, S. Dai, P. Marrack, and J. W. Kappler. 
2009. Many different Vbeta CDR3s can reveal the inherent MHC reactivity of germline-
encoded TCR V regions. Proc. Natl. Acad. Sci. USA 106: 7951-7956. 
4. Felix, N. J., D. L. Donermeyer, S. Horvath, J. J. Walters, M. L. Gross, A. Suri, and P. M. 
Allen. 2007. Alloreactive T cells respond specifically to multiple distinct peptide-MHC 
complexes. Nat. Immunol. 8: 388-397. 
5. Felix, N. J., W. J. Brickey, R. Griffiths, J. Zhang, L. Van Kaer, T. Coffman, and J. P. 
Ting. 2000. H2-DMalpha(-/-) mice show the importance of major histocompatibility 
complex-bound peptide in cardiac allograft rejection. J. Exp. Med. 192: 31-40. 
6. Morris, G. P., P. P. Ni, and P. M. Allen. 2011. Alloreactivity is limited by the 
endogenous peptide repertoire. Proc. Natl. Acad. Sci. USA 108: 3695-3700. 
7. Morris, G. P., and P. M. Allen. 2009. Cutting edge: Highly alloreactive dual TCR T cells 
play a dominant role in graft-versus-host disease. J. Immunol. 182: 6639-6643. 
8. Colf, L. A., A. J. Bankovich, N. A. Hanick, N. A. Bowerman, L. L. Jones, D. M. Kranz, 
and K. C. Garcia. 2007. How a single T cell receptor recognizes both self and foreign 
MHC. Cell 129: 135-146. 
9. Macdonald, W. A., Z. Chen, S. Gras, J. K. Archbold, F. E. Tynan, C. S. Clements, M. 
Bharadwaj, L. Kjer-Nielsen, P. M. Saunders, M. C. Wilce, F. Crawford, B. Stadinsky, D. 
Jackson, A. G. Brooks, A. W. Purcell, J. W. Kappler, S. R. Burrows, J. Rossjohn, and J. 
McCluskey. 2009. T cell allorecognition via molecular mimicry. Immunity 31: 897-908. 
10. Luz, J. G., M. Huang, K. C. Garcia, M. G. Rudolph, V. Apostolopoulos, L. Teyton, and I. 
A. Wilson. 2002. Structural comparison of allogeneic and syngeneic T cell receptor-
peptide-major histocompatibility complex complexes: a buried alloreactive mutation 
subtly alters peptide presentation substantially increasing V(beta) Interactions. J. Exp. 
Med. 195: 1175-1186. 
11. Hennecke, J., and D. C. Wiley. 2002. Structure of a complex of the human alpha/beta T 
cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major 
histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): 
insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195: 571-581. 
12. Reiser, J. B., C. Darnault, C. Gregoire, T. Mosser, G. Mazza, A. Kearney, P. A. van der 
Merwe, J. C. Fontecilla-Camps, D. Housset, and B. Malissen. 2003. CDR3 loop 
flexibility contributes to the degeneracy of TCR recognition. Nat. Immunol. 4: 241-247. 
13. Feng, D., C. J. Bond, L. K. Ely, J. Maynard, and K. C. Garcia. 2007. Structural evidence 
for a germline-encoded T cell receptor-major histocompatibility complex interaction 
'codon'. Nat. Immunol. 8: 975-983. 
14. Dai, S., E. S. Huseby, K. Rubtsova, J. Scott-Browne, F. Crawford, W. A. Macdonald, P. 
Marrack, and J. W. Kappler. 2008. Crossreactive T Cells spotlight the germline rules for 
alphabeta T cell-receptor interactions with MHC molecules. Immunity 28: 324-334. 
	   149	  
15. Morris, G. P., G. L. Uy, D. Donermeyer, J. F. Dipersio, and P. M. Allen. 2013. Dual 
receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host 
disease. Science translational medicine 5: 188ra174. 
16. Hahn, M., M. J. Nicholson, J. Pyrdol, and K. W. Wucherpfennig. 2005. Unconventional 
topology of self peptide-major histocompatibility complex binding by a human 
autoimmune T cell receptor. Nat. Immunol. 6: 490-496. 
17. Bulek, A. M., D. K. Cole, A. Skowera, G. Dolton, S. Gras, F. Madura, A. Fuller, J. J. 
Miles, E. Gostick, D. A. Price, J. W. Drijfhout, R. R. Knight, G. C. Huang, N. Lissin, P. 
E. Molloy, L. Wooldridge, B. K. Jakobsen, J. Rossjohn, M. Peakman, P. J. Rizkallah, and 
A. K. Sewell. 2012. Structural basis for the killing of human beta cells by CD8(+) T cells 
in type 1 diabetes. Nat. Immunol. 13: 283-289. 
18. Stark, J. L., and A. H. Cross. 2006. Differential expression of suppressors of cytokine 
signaling-1 and -3 and related cytokines in central nervous system during remitting 
versus non-remitting forms of experimental autoimmune encephalomyelitis. Int. 
Immunol. 18: 347-353. 
19. Fritz, R. B., C. H. Chou, and D. E. McFarlin. 1983. Relapsing murine experimental 
allergic encephalomyelitis induced by myelin basic protein. J. Immunol. 130: 1024-1026. 
20. Slavin, A., C. Ewing, J. Liu, M. Ichikawa, J. Slavin, and C. C. Bernard. 1998. Induction 
of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin 
oligodendrocyte glycoprotein. Autoimmunity 28: 109-120. 
21. Huseby, E. S., J. White, F. Crawford, T. Vass, D. Becker, C. Pinilla, P. Marrack, and J. 
W. Kappler. 2005. How the T cell repertoire becomes peptide and MHC specific. Cell 
122: 247-260. 
22. Hornell, T. M., J. C. Solheim, N. B. Myers, W. E. Gillanders, G. K. Balendiran, T. H. 
Hansen, and J. M. Connolly. 1999. Alloreactive and syngeneic CTL are comparably 
dependent on interaction with MHC class I alpha-helical residues. J. Immunol. 163: 
3217-3225. 
23. Obst, R., N. Netuschil, K. Klopfer, S. Stevanovic, and H. G. Rammensee. 2000. The role 
of peptides in T cell alloreactivity is determined by self-major histocompatibility 
complex molecules. J. Exp. Med. 191: 805-812. 
24. Penn, D. J., K. Damjanovich, and W. K. Potts. 2002. MHC heterozygosity confers a 
selective advantage against multiple-strain infections. Proc. Natl. Acad. Sci. USA 99: 
11260-11264. 
25. McClelland, E. E., D. J. Penn, and W. K. Potts. 2003. Major histocompatibility complex 
heterozygote superiority during coinfection. Infection and immunity 71: 2079-2086. 
26. Flesch, I. E., W. P. Woo, Y. Wang, V. Panchanathan, Y. C. Wong, N. L. La Gruta, T. 
Cukalac, and D. C. Tscharke. 2010. Altered CD8(+) T cell immunodominance after 
vaccinia virus infection and the naive repertoire in inbred and F(1) mice. J. Immunol. 
184: 45-55. 
27. Day, E. B., K. L. Charlton, N. L. La Gruta, P. C. Doherty, and S. J. Turner. 2011. Effect 
of MHC class I diversification on influenza epitope-specific CD8+ T cell precursor 
frequency and subsequent effector function. J. Immunol. 186: 6319-6328. 
28. Bill, J., V. B. Appel, and E. Palmer. 1988. An analysis of T-cell receptor variable region 
gene expression in major histocompatibility complex disparate mice. Proc. Natl. Acad. 
Sci. USA 85: 9184-9188. 
	   150	  
29. Brown, N. K., D. J. McCormick, C. S. David, and Y. C. Kong. 2008. H2E-derived Eα52-
68 peptide presented by H2Ab interferes with clonal deletion of autoreactive T cells in 
autoimmune thyroiditis. J. Immunol. 180: 7039-7046. 
30. Christadoss, P., C. S. David, M. Shenoy, and S. Keve. 1990. Ek α transgene in B10 mice 
suppresses the development of myasthenia gravis. Immunogenetics 31: 241-244. 
31. Gonzalez-Gay, M. A., G. H. Nabozny, M. J. Bull, E. Zanelli, J. Douhan, 3rd, M. M. 
Griffiths, L. H. Glimcher, H. S. Luthra, and C. S. David. 1994. Protective role of major 
histocompatibility complex class II Ebd transgene on collagen-induced arthritis. J. Exp. 
Med. 180: 1559-1564. 
32. Merino, R., M. Iwamoto, L. Fossati, P. Muniesa, K. Araki, S. Takahashi, J. Huarte, K. 
Yamamura, J. D. Vassalli, and S. Izui. 1993. Prevention of systemic lupus erythematosus 
in autoimmune BXSB mice by a transgene encoding I-E α chain. J. Exp. Med. 178: 1189-
1197. 
33. Nayak, J. L., and A. J. Sant. 2012. Loss in CD4 T-cell responses to multiple epitopes in 
influenza due to expression of one additional MHC class II molecule in the host. 
Immunology 136: 425-436. 
34. Nishimoto, H., H. Kikutani, K. Yamamura, and T. Kishimoto. 1987. Prevention of 
autoimmune insulitis by expression of I-E molecules in NOD mice. Nature 328: 432-434. 
35. Reich, E. P., R. S. Sherwin, O. Kanagawa, and C. A. Janeway, Jr. 1989. An explanation 
for the protective effect of the MHC class II I-E molecule in murine diabetes. Nature 341: 
326-328. 
36. Lund, T., L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. Chandler, 
J. Dyson, J. K. Picard, A. Edwards, and et al. 1990. Prevention of insulin-dependent 
diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A β-
chain or normal I-E α-chain. Nature 345: 727-729. 
 
 
 151 
VITAE 
Peggy P. Ni 
 
E-mail address:  ppni@wustl.edu 
 
Mailing address:  4961 Laclede Ave. APT 203, St. Louis, MO 63108 
 
Education:  Ph.D. Biology and Biomedical Sciences (Immunology)  
   expected August 2014  
   Washington University in St. Louis 
 
   B.A. Molecular and Cell Biology, with an emphasis in Immunology  
   May 2008, Department Honors 
      University of California, Berkeley 
 
Awards and Honors:  American Heart Association (Midwest Affiliate) Pre-doctoral fellowship  
   July 2010 – July 2012 
 
UC Berkeley Molecular and Cell Biology Honors Research Program  
   Aug. 2007 – May 2008 
 
Research Experience: Pre-doctoral trainee, laboratory of Dr. Paul Allen 
      Washington University of St. Louis: St. Louis, MO 
      Jan. 2009 – Present 
   Investigate how CD4+ T cell alloreactivity compares to conventional  
recognition. Examine the contribution of dual TCR T cells and MHC    
repertoire to alloreactivity. 
 
Undergraduate research assistant, laboratory of Dr. Daniel Portnoy 
   University of California, Berkeley: Berkeley, CA 
   Oct. 2006 – May 2008 
Studied the effects of the Listeria monocytogenes pentose phosphate    
   pathway on the host immune response. 
 
Process sciences and engineering intern 
   PDL BioPharma, Inc.: Fremont, CA 
   June 2006 – Aug. 2006 
Generated cell lines that produce monoclonal antibodies used for     
   therapeutics. Developed an assay to assess the stability of antibody  
   production of these cell lines. 
 
 
Publications:  
  
Ni, P. P., Y. Wang, and P. M. Allen. 2014. Both positive and negative effects on immune  
responses by expression of a second class II MHC molecule. Submitted. 
 152 
 
Ni, P. P., B. Solomon, C. S. Hsieh, P. M. Allen, and G. P. Morris. 2014. The ability to rearrange  
dual TCRs enhances positive selection, leading to increased allo- and autoreactive T cell 
repertoires. Submitted. 
 
Morris, G. P., P. P. Ni, and P. M. Allen. 2011. Alloreactivity is limited by the endogenous  
peptide repertoire. Proc. Natl. Acad. Sci. USA 108: 3695-700. 
 
Crimmins G. T., M. W. Schelle, A. A. Herskovits, P. P. Ni, B. C. Kline, N. Meyer-Morse, A. T.  
Iavarone, and D. A. Portnoy. 2009. Listeria monocytogenes 6-phosphogluconolactonase 
(pgl) mutants induce increased activation of a host cytosolic surveillance pathway. Infect. 
Immun. 77: 3014-22. 
 
 
Conference Abstracts: 
 
Ni, P. P., P. M. Allen, and G. P. Morris. Generation of secondary TCRs is critical for T cell  
development and the formation of an alloreactive T cell repertoire. 
American Association of Immunologists Meeting 2013, Oral presentation and poster 
 
Ni, P. P. and P. M. Allen. A direct comparison of alloreactive and conventional T cell  
recognition. 
 Euthyme-Rolduc Meeting 2011, Poster presentation 
